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ABSTRACT 
 
Staphylococcus pseudintermedius is an opportunistic pathogen in dogs and 
is the most frequent cause of canine pyoderma. The recent emergence of 
methicillin resistance and multidrug resistance has made it increasingly difficult to 
treat infections using conventional antibiotics. There is an urgent need for 
alternative strategies to prevent S. pseudintermedius infections. The development 
of a successful vaccine against S. pseudintermedius is complicated by several 
virulence and immune evasion factors. The objective of this project was to identify 
new targets for treatment and prophylaxis of methicillin-resistant and multidrug-
resistant S. pseudintermedius infection. This was achieved using two strategies 
(a) understanding the roles of Protein A and Sortase A during pathogenesis, along 
with exploring Sortase A inhibition as an alternate treatment strategy (b) analyzing 
the surface-associated and secreted proteins in S. pseudintermedius to identify 
novel vaccine targets.  
In this study, a 3-D homology model for Sortase A was generated using 
molecular dynamic simulation. Using this model, drug databases were screened 
in silico and potential inhibitors of Sortase A were identified and tested in cell-free 
and functional whole-cell assays. Four promising compounds were identified using 
this strategy. Sortase A anchors proteins to the bacterial surface. These include 
potent virulence and immune evasion factors such as Protein A. Both cell wall-
associated and secreted Protein A in S. pseudintermedius was characterized and 
its role in immune evasion was examined. Since Sortase A inhibition alone may 
not be an effective treatment option, the entire secretome and the surface-
associated proteins in S. pseudintermedius were analyzed by mass spectrometry. 
Eight orthologous proteins across several S. pseudintermedius isolates were 
identified that could serve as potential vaccine targets. Ultimately, Sortase A 
inhibition along with a multicomponent vaccine containing a non-toxigenic version 
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of Protein A and other potential B-cell/T-cell epitopes may be effective against S. 
pseudintermedius infection.  
 This study is an important step in (i) understanding the nature of 
immunoglobulin binding onto Protein A and (ii) the inhibition of Sortase A as an 
alternate treatment strategy in S.pseudintermedius, and may ultimately pave the 
way towards the development of a successful vaccine against S. pseudintermedius 
infection.  
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INTRODUCTION  
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Introduction and Review of Literature 
 
The recent emergence of methicillin resistance and multidrug resistance in 
Staphylococcus aureus and Staphylococcus pseudintermedius has shifted the 
focus of research from conventional antibiotic-based therapies to the development 
of novel therapeutics or prophylactic means of dealing with these bacteria. This, in 
part, has been a challenge due to the heterogeneity of the species. There are two 
factors that play a crucial role in the development of a successful vaccine; (a) broad 
understanding of the nature of host immune response to staphylococcal infections 
and (b) the role of bacterial surface proteins and secreted virulence factors in 
pathogenesis. 
 
Introduction to Staphylococcus pseudintermedius 
S. pseudintermedius is a Gram-positive coccus. It is a commensal and an 
opportunistic pathogen in dogs, implicated as the most frequent cause of canine 
pyoderma. It causes other infections, including those of the urinary tract, wounds, 
and otitis externa. It has zoonotic potential and can cause sporadic infections in 
humans as well [1-5]. S. pseudintermedius was classified as a new species in 
2005. Until then, it was classified as S. intermedius. Since its reclassification,  
S. pseudintermedius has been the most common staphylococcal species 
associated with infections in dogs. As with any ‘new’ species, there is a lot to 
discover in terms of genotype and phenotype and to understand any similarities or 
differences at the molecular level. Much of what is known today about this 
bacterium comes from comparative studies with S. aureus. Similar to S.aureus, 
the incidence of methicillin resistance and multidrug resistance in this species has 
been increasing in the past few years. This has made treatment of infection difficult 
especially in the veterinary setting due to the limited number of drug choices that 
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are available currently [6]. Therefore, there is an urgent need for the development 
of alternate treatment strategies.   
 
History and Characterization 
Staphylococcus intermedius was first described in 1976 and was thought to be the 
causative agent of skin infections in dogs. Advancements in molecular techniques 
led to the identification of a novel species, S. pseudintermedius, in 2005 as the 
causative agent of pyoderma and other skin infections in dogs [7]. Isolates that 
were previously classified as S. intermedius based on phenotypic methods were 
reclassified based on molecular typing methods. Thus, the Staphylococcus 
intermedius group (SIG) was created consisting of three species, namely, S. 
intermedius (type strain of pigeon origin), S. pseudintermedius (common causative 
agent of skin infections in dogs) and S. delphini (first isolated from purulent skin 
lesions of dolphins in 1988) [8].  
 
Identification and Typing  
Traditionally, isolates from canine skin infections had been identified by colony 
morphology and standard phenotypic tests, but in recent times, this has been 
complicated due to changes in the taxonomy of the species. Phenotypic methods 
are not reliable for distinguishing between members of the SIG. S. intermedius can 
be distinguished from S. pseudintermedius by a combination of biochemical tests 
that include arginine dihydrolase test, β-gentiobiose test and D-mannitol test. 
Currently, there are no known biochemical tests that can reliably distinguish 
between S. pseudintermedius and S. delphini [7].Clinical identification of  
S. pseudintermedius in a diagnostic setting relies on the fact that S. intermedius 
and S. delphini are not associated with infections in dogs. Molecular methods are 
the only way by which it is possible to correctly identify the species within the SIG. 
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Isolates previously identified as S. intermedius in dogs have now been classified 
as S. pseudintermedius based on molecular typing methods [7, 8].  
 
Molecular (Genomic) Methods for Species Identification 
 
The first molecular method that was discriminative for S. intermedius and  
S. pseudintermedius was phylogenetic analysis based on partial sequences of 
sodA gene and hsp60 gene. Since then, various DNA-based methods have been 
developed primarily for typing and epidemiological surveillance. These include 
ribotyping, PFGE, spa typing, SCC-mec typing, and various PCR-based methods 
[7, 8]. S. pseudintermedius can be distinguished from S. intermedius and 
S.delphini by a polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP). This method relies on the presence of a single MboI 
restriction site in the pta gene of S. pseudintermedius, which is absent in S. 
intermedius and S.delphini. The only disadvantage of this method is the 
heterogeneity associated with the MboI site in a small proportion of the 
S.pseudintermedius strains which either results in the absence of the restriction 
site or an additional band. A similar approach but with a different gene, the kat 
gene harboring the restriction site for TaqI restriction endonuclease, has also been 
evaluated for species identification of coagulase-positive staphylococci [8-10]. 
Another method for routine species identification of coagulase-positive 
staphylococci in veterinary medicine is based on a multiplex PCR developed by 
Sasaki et al. targeting the thermonuclease (nuc) gene [11]. 
 
Pulsed-field gel electrophoresis (PFGE) is one other method for bacterial typing in 
general. It is based on analysis of the DNA fingerprint of the bacteria generated 
upon treatment with selected restriction endonucleases. It has high discriminatory 
power compared to other typing methods. PFGE for  
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S. pseudintermedius is done using a protocol that was developed for S. aureus but 
with slight modifications. Although this method is useful in studies investigating the 
clonal relationships between MRSP isolates, it is time consuming and difficult to 
standardize for inter-laboratory comparison. There are several modifications of the 
protocol using the SmaI restriction endonuclease, making it difficult to share and 
communicate PFGE data [7, 8, 12-14].  
 
Staphylococcal Protein A (spa) typing developed by Moodley et al. is based on the 
sequence variation of the polymorphic X-region of the spa gene. It is currently 
employed for easy and rapid typing of S. pseudintermedius. It has high 
discriminatory power and allows data sharing and harmonization between labs. 
There are about 53 spa types, although an online database for this is currently not 
available [5, 8, 15].  
 
Multilocus Sequence Typing (MLST) is a valuable method for genotyping bacteria 
based on variation in the sequence of slowly evolving housekeeping genes. Data 
from MLST is portable, accurate and useful for global epidemiological studies 
involving population genetic of bacteria. The earlier version of MLST was based 
on four loci [16]. The current MLST scheme, which uses seven genes, developed 
by Solyman et al. [6] has greater genetic diversity and discriminatory power 
compared to other typing methods. The housekeeping genes used for this typing 
scheme are tuf, cpn60, pta, purA, fdh, sar and ack. Based on the MLST scheme, 
the predominant clonal population in the United States and Europe are designated 
ST68 and ST71, respectively [12].  
 
Staphylococcal chromosome cassette mecA (SCC mec) typing is based on the 
sequence variation in the mobile genetic element (MGE), SCCmec. The SCCmec 
region comprises the mecA gene, the cassette chromosome recombinase (ccr) 
gene and three joining regions (J1-J3). The mecA gene is responsible for 
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conferring methicillin resistance. Therefore this typing method can be applied to 
only methicillin resistant isolates. Based on the allotype of the ccr, the class of 
mecA gene complex and sequence variation in the joining regions, there are at 
least ten SCCmec types that are known, designated I-X [17] .  
 
Automated systems designed for high-throughput screening and identification of 
human pathogens such as microarrays may be used for S. pseudintermedius as 
well, but because they are not designed for veterinary pathogens, their accuracy 
in identification of veterinary pathogens is debatable. Most recently, a matrix 
assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF 
MS) has been developed for species differentiation within the SIG [18].  
 
Pathogenesis of S. pseudintermedius  
 
S. pseudintermedius is an opportunistic pathogen. It does not cause any disease 
unless the immune system of the host is compromised or there is a breach in the 
external skin barrier, such as wounds and surgical procedures or other factors 
predisposing the host to atopic dermatitis. The pathogenesis of  
S. pseudintermedius remains largely unknown. Some genetic lineages and 
sequence types are more virulent than the others and the reason behind this is not 
fully understood [7] . Host factors likely play a crucial role in the pathogenesis of 
S. pseudintermedius infection [8]. S. pseudintermedius adheres better to 
corneocytes of atopic dogs whether sampled from an inflamed area or not, than 
corneocytes of healthy dogs. There could be several reasons for this including a 
change in the immune status of the dog or altered expression of surface adhesins 
in atopic dogs compared to healthy dogs. More research in this area is needed to 
fully understand the complex nature of host-pathogen interaction [19-21].  
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Virulence Factors and Immune Evasion Factors Produced by 
S. pseudintermedius  
 
S. pseudintermedius produces a number of virulence factors, including some 
functionally related to those produced by S.aureus [22]. Recent advancements in 
genome sequencing technology and bioinformatics have added a wealth of 
information to the current knowledge with respect to proteins and virulence factors 
produced by S. pseudintermedius.  
 
S. pseudintermedius produces several enzymes that are involved in virulence such 
as coagulase, proteases, hyaluronidase, phospholipase, staphylokinase and 
thermonuclease. It produces toxins such as leukocidins, exotoxins, leukotoxins, 
exfoliative toxins, enterotoxins and hemolysins [8].  
S. pseudintermedius also has the ability to bind to fibrinogen, fibronectin and 
cytokeratin using surface molecules that serve as microbial surface components 
recognizing adhesive matrix molecules (MSCRAMM) [8, 22].  
S. pseudintermedius produces the immunoglobulin binding protein, Protein A, 
which is similar to that found in S. aureus.  Predicted Protein A genes from  
S. pseudintermedius have been identified but their role in virulence and immune 
evasion are yet to be determined [5]. 
 
Cytotoxins 
 
S. pseudintermedius produces α-hemolysin and β-hemolysin and causes 
hemolysis of rabbit erythrocytes and hot-cold hemolysis of sheep erythrocytes [23-
25]. The β-hemolysin from S. pseudintermedius has high-affinity 
sphingomyelinase activity and is responsible for the characteristic partial zone of 
hemolysis observed around colonies on sheep blood agar [8, 22]. It also produces 
a bicomponent leukotoxins, Luk-I, encoded by two co-transcribed genes, lukS and 
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lukF, which has leucktoxic activity on polymorphonuclear cells. Luk-I is associated 
with the most predominant clonal population in Europe, ST71, particularly 
methicillin-resistant isolates [7, 8, 22]. 
 
Exfoliative toxin 
 
S. pseudintermedius produces an exfoliative toxin called SIET. This toxin causes 
a rounding effect on cultured epithelial cells. In animal models, SIET was shown 
to cause an exfoliative effect in 1-day-old chickens, hamsters and dogs but not in 
rats and mice. Dogs that were injected with purified SIET developed clinical signs 
such as erythema, exfoliation and crusting similar to symptoms seen in canine 
pyoderma, human staphylococcal scalded skin syndrome and porcine exudative 
epidermitis (greasy pig disease). A second exfoliative toxin EXI (renamed ExpA) 
encoded by the exi gene has been identified in S. pseudintermedius. The predicted 
protein shows about 43-68% sequence identify with known staphylococcal 
exfoliative toxins. A recombinant version of this protein caused exfoliative skin 
lesions in neonatal mice. Apart from SIET and EXI, a third exfoliative toxin ExpB 
has been identified in S. pseudintermedius, which causes intraepidermal splitting 
and degradation of desmoglein-a (Dsg-1) [8, 22].  
 
Enterotoxins and Superantigens 
 
S. pseudintermedius produces proteins that cross-react with antibodies raised 
against staphylococcal enterotoxins (SEs) and superantigens (SAs); SEA, SEB, 
SEC, SED and toxic shock syndrome toxin-1 (TSST-1) [8, 22, 26]. A canine type 
C enterotoxin (SEC canine) has been identified from canine pyoderma isolates. This 
is distinct from other staphylococcal enterotoxins but shares their ability to induce 
vomiting and T-cell proliferation [27]. A novel enterotoxin-related gene, se-int was 
detected by PCR but its function remains to be examined [24, 28].  
9 
 
Cell-Wall Associated Proteins 
 
Cell wall-associated (CWA) proteins, such as microbial surface components 
recognizing adhesive matrix molecules (MSCRAMMs), play a crucial role in 
bacterial attachment to the host extracellular matrix. The repertoire of MSCRAMMs 
in each bacterial species contributes to its host adaptation and survival. CWA 
proteins are characterized by an N-terminal signal sequence, LPXTG motif, 
tandem repeats and immunoglobulin-like folds. Several CWA proteins have been 
identified in S. pseudintermedius, designated as ‘Sps’ (Staphylococcus 
pseudintermedius surface proteins). In particular, the isolate ED99 has at least 19 
putative CWA proteins designated SpsA through SpsR [15, 29]. Many strains 
adhere to fibrinogen, fibronectin, cytokeratin 10, elastin, collagen type 1, vitronectin 
and laminin [29, 30]. Much remains to be understood about the interaction of S. 
pseudintermedius with the host extracellular matrix.  
 
Protein A 
Protein A in S. aureus 
Protein A is one of the most potent immune evasion factors in S. aureus [31]. It is 
a cell wall-associated protein that binds to IgG from various mammals including 
goat, rabbit, mouse and humans specifically via its Fcγ region. This binding in the 
‘wrong’ orientation prevents it from binding to Fc receptors on immune cells such 
as neutrophils, thereby preventing opsonization and phagocytosis [32-35] . Binding 
of Protein A to IgG also prevents it from activating the complement via C1q. Both 
the classical and alternate pathways of the complement can be inhibited by virtue 
of this binding [36-39]. Thus, S. aureus evades the immune system and causes 
persistent infections.  
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Protein A is also secreted into the extracellular milieu during staphylococcal growth 
and active infection [40-43]. The secreted form of Protein A functions as a B-cell 
super antigen (SAg). It binds to VH3 B-cell receptors and limits their ability to 
produce antibodies. Also, marginal zone B cells and B-1 cells undergo, 
preferentially, induced cell death with supraclonal depletion and immune tolerance 
upon exposure to Protein A. There is a clonal expansion at first followed by rapid 
apoptosis of B-cells. Thus, Protein A may limit the efficacy of a vaccine that 
depends on opsonophagocytic antibody production. It can also interfere with 
vaccine efficacy by binding to B-cells and interfering with their function [44-48].   
 
Structure and Function  
Protein A is encoded by the spa (staphylococcal protein A) gene. The spa gene in 
S. aureus is variable in length with approximately 1500bp. It encodes a protein of 
about 480-500 amino acids with a molecular weight of ~40-60kDa [49, 50]. It is 
synthesized as a precursor with an N-terminal signal sequence and a C-terminal 
sorting peptide. The N-terminal part of SpA consists of four to five repeats of 56-
61 amino acids that serve as immunoglobulin binding domains (IgBD), designated 
E,D,A,B and C, followed by a variable region, X [51]. The C-terminal region X is 
comprised of Xr, a highly repetitive yet variable octapeptide, and Xc, a domain with 
unique sequence in close proximity to the cell wall anchor structure of SpA [52]. 
The C-terminal also harbors an LPXTG motif which is recognized by the 
transpeptidase enzyme Sortase A, responsible for anchoring the protein to the 
pentaglycine residues of the peptidoglycan cell wall. Each IgBD folds into a triple-
helical bundle, connected by short linkers with specific binding sites for Fcγ and 
VH3 Fab domains of human and animal immunoglobulin. Glutamine (Q) residues 
in position 9 and 10 in the α-helix 1 of each IgBD are critical for Fcγ binding, thereby 
preventing antibody-mediated opsonization and phagocytosis. Aspartic acid (D) 
residues in position 36 and 37 in the linker region between α-helix 2 and 3 of each 
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IgBD are essential for Fab binding of VH3-type IgG and IgM. This association 
triggers the B-cell superantigen activity of Protein A. spa mutants have been shown 
to be more susceptible to opsonophagocytic killing and are unable to block 
adaptive immune responses in mouse models of S.aureus infection. Kim et al. 
have demonstrated that a nontoxigenic Protein A variant, SpAKKAA, with 20 amino 
acid substitutions replacing Q9 and Q10 with lysine (K) as well as D36 and D37 with 
alanine (A) in each of the immunoglobulin binding domains, cannot bind Fcγ or VH3 
Fab domains [53]. Immunization of mice with SpAKKAA elicited antibodies that 
neutralized immunoglobulin-binding activities of Protein A, conferred some 
protection in a mouse model of S. aureus infection, and augmented 
immunogenicity of unrelated antigens [53, 54]. SpAKKAA monoclonal antibodies 
promoted opsonophagocytic killing of S.aureus in mouse and human blood, 
provided protection from abscess formation, and stimulated pathogen-specific 
immune responses in a mouse model of staphylococcal disease [54, 55]. A 
monoclonal antibody that specifically recognizes the E domain of SpA has also 
been developed which neutralizes only the E domain of SpA but does not provide 
disease protection in mice [44, 55]. 
 
Protein A in S. pseudintermedius  
A putative staphylococcal protein A (spa) gene was initially described by Moodley 
et al. in 2008 in the S. pseudintermedius isolate ED99 [5]. This gene was used to 
develop a species-specific spa typing protocol. The spa gene in ED99 is 1389bp 
in length and has 68% nucleotide and 55% predicted amino acid identity to the 
homologous gene in the S. aureus reference strain 8325-4 where Protein A was 
originally described. The predicted protein contained functional regions and 
conserved domains similar to those described in S.aureus, including four IgG-
binding domains and a polymorphic X-region [5, 15]. The sequence variation in the 
variable region X in S. pseudintermedius had duplications or deletions of whole 
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repeats or point mutations within the repeats. Lack of IgG-binding domain region 
B (58 amino acids) partly accounted for the shorter protein in  
S. pseudintermedius ED99 [5]. Bannoehr et al. in 2011 suggested that there were 
two predicted orthologues of S. aureus Protein A in ED99, SpsP (designated as 
Spa2) and SpsQ (which is a full-length Protein A designated as Spa1). The genes 
are located along the oriC part of the genome and are adjacent to each other [15].  
 
spsP 
The spsP gene encodes a protein that consists of 377 amino acids in ED99. This 
protein is 73% identical to SpsQ at the amino acid level. It has a predicted N-
terminal sequence of 33 amino acids, followed by a repeat region consisting of 
three predicted IgG-binding domains. Each IgG-binding domain consists of 55 
amino acids with 78%-85% identity between domains. The C-terminal region has 
a predicted X-region which shares 63% overall sequence similarity to the X-region 
of S.aureus [15]. 
 
spsQ 
The spsQ gene encodes a protein that is 462 amino acids in ED99. It has a 
predicted N-terminal sequence of 33 amino acids, followed by a repeat region 
consisting of four IgG-binding domains. Domains 1 and 2 have 59 amino acids; 
domain 3 has 55 amino acids while domain 4 has 52 amino acids. The domains 
have between 59%-86% protein sequence identity. The repeated IgG-binding 
domains are conserved between SpsP and SpsQ, with 67% to 90% sequence 
identity in pairwise alignments. The C-terminal region consist of a predicted X-
region which consists of a 77 amino acid-long repeat sequence (Xr) and a constant 
region (Xc) with 70% similarity to the X-region of S. aureus. The Xr repeat region 
of SpsQ was used by Moodley et al. to develop the spa typing method for S. 
pseudintermedius [5, 15]. Whole genome sequencing of several  
S. pseudintermedius isolates in this lab has shown that most isolates have a full-
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length spsQ gene while they may or may not harbor the full length spsP gene. 
Some have a truncated spsP gene or the gene may be split into two separate 
fragments.  
Sortase A 
Role of Sortase A in Protein Anchoring  
Sortase A is a cysteine transpeptidase enzyme that is produced by most Gram-
positive bacteria. Surface proteins in Gram-positive bacteria play a crucial role 
during pathogenesis. The main function of Sortase A is to anchor surface proteins 
with an N-terminal LPXTG motif on to the peptidoglycan cell wall. Sortase A 
substrates function as adhesins, internalins, blood clotting and immune evasion 
factors, and transporters for nutrients across the microbial cell wall envelope [56]. 
Sortase A-deficient mutants of S. aureus fail to assemble LPXTG proteins on their 
surface and are unable to form abscess lesions in organs or cause lethal 
bacteremia in animal models of infection [57].  
 
Sortase A is the prototypical enzyme for members of the class A family (house-
keeping sortase) and has been widely studied. Sortase A is present in Firmicutes, 
and is responsible for anchoring of proteins that mediate bacterial adhesion. Other 
sortase genes and their corresponding enzymes have been identified.  Class B 
(sortase B) enzymes are responsible for attaching hemoglobin receptors to the 
peptidoglycan cell wall and in the assembly of pili. These enzymes are also present 
in Firmicutes. Class C sortases function as pilin polymerases and anchor pili on 
bacterial surfaces. Class D sortases are found in bacilli and streptomyces and are 
expressed during sporulation. Other less studied sortases include Class E and F 
enzymes in actinobacteria whose functions are unknown [56, 58-60]. 
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Sortase A in S. aureus  
 
Structure and Function  
Sortase A in S. aureus has been well studied and characterized. The srtA gene in 
S. aureus is 618bp in length. It encodes a 206-amino acid protein with an N-
terminal hydrophobic segment that functions as a signal peptide for secretion and 
as a stop transfer signal for membrane anchoring. The C-terminal cell wall sorting 
signal typically consists of a 35-reside peptide with an LPXTG motif, followed by a 
hydrophobic domain and a positively charged tail [61]. The enzyme adopts a type 
II membrane topology, with the N-terminus inside the cytoplasm and the C-terminal 
enzymatic portion located across the plasma membrane [62]. NMR spectroscopy 
and X-ray crystallography of Sortase A revealed that the enzyme assumes a 
unique fold, consisting of an eight-stranded β-barrel that includes one or two 
helices and several loops. Strands β7 and β8 form the floor of the hydrophobic 
depression where the active site is located. Within the active site are the highly 
conserved Cys184 and His120. The Cys184 is anchored in β7, while the His120 is 
located within a helical region that connects β3 and β3, with its imidazole group in 
the vicinity of the sulfhydryl side chain of Cys184. Arg197 is another amino acid 
anchored in β8 that is located in close proximity and parallel to the active-site 
cysteine [63]. Amino acid replacement of either Cys184 or His120 completely 
abolished the activity of Sortase A both in vivo and in vitro and replacement of 
Arg197 greatly reduced its enzymatic activity. Thr180, Ile182, and Ala118 are involved 
in recognition and stabilization of bound substrate. Amino acid substitutions in 
each of these residues can have profound effect on enzyme activity. It has been 
observed that the presence of Ca2+ ions greatly enhances the activity of the 
enzyme [56, 63-68].  
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Surface proteins are synthesized in the bacterial cytoplasm as precursors 
harboring an N-terminal signal peptide and a C-terminal sorting signal comprising 
the LPXTG motif (P1 precursor) [64]. The surface proteins are then initiated into 
the Sec secretion pathway. Signal peptidase cleaves the N-terminal signal peptide 
to generate the P2 precursor. The hydrophobic domain of the sorting signal is 
thought to retain the polypeptide in the membrane, thereby allowing the LPXTG 
motif to be recognized by Sortase A. The sulfhydryl group of the active site Cys184 
(possibly activated for deprotonation by Agr197) performs a nucleophilic attack at 
the peptide bond between the threonine and glycine residue of the conserved 
LPXTG. This generates an acyl-enzyme intermediate that undergoes a 
nucleophilic attack by the amino group of the pentaglycine (Gly5) cross-bridge 
within the peptidoglycan precursor lipid II and forms the P3 intermediate. P3 
intermediates are subsequently covalently incorporated into the peptidoglycan cell 
wall via the transpeptidation and transglycosylation reactions of the cell wall 
biosynthesis, ultimately giving rise to the mature product (M). Thus, the surface 
proteins are covalently linked at the C-terminal end to the cell wall envelope [56, 
57, 63, 69].  
 
Sortase A in S. pseudintermedius  
Our lab is currently studying Sortase A and trying to find inhibitors that can 
effectively block Sortase A activity. A putative srtA gene was identified from whole 
genome sequences of various isolates representing the major clonal populations 
in the United States and Europe. Based on the predicted protein sequence, 
functional domains were identified. Sortase A in S. pseudintermedius is 57% 
identical to S. aureus Sortase A at the protein level. They share the same sortase 
family domains. Multiple sequence alignment of srtA gene from several S. 
pseudintermedius isolates revealed that the gene is 597bp in length, 21bp shorter 
than that found in S. aureus. It encodes a protein with 198 amino acids with a 
16 
 
theoretical molecular weight of 22.3kDa. As with S. aureus Sortase A, it contains 
highly conserved amino acids. Based on homology modeling and active site 
prediction done as part of this project, Cys177, His114, and Arg190 are predicted to 
be present in the active site and critical for enzyme activity. The crystal structure 
and NMR spectra of S. pseudintermedius Sortase A are yet to be resolved. 
However, based on the conservation of amino acids and predicted structural 
similarity, it is hypothesized that Sortase A in S. pseudintermedius performs a 
similar function as Sortase A in S. aureus. The predicted amino acid sequence of 
Sortase A in S. pseudintermedius with the amino acids involved in catalytic activity 
(highlighted) is as follows: 
 
MQKLTRGLVPLIGIALILAGVYLIFKPKIDAYLTNKENEQKIEVYEESQQNAPSKVPEI
PKDPSKVVGVLEVPSVGIKEAVYPGPATPEQLERGVSLAEKDESLKDQNIAIAGHTNYS
LNYQFTELHKAKKGAEVIFKLGKETRKYQITSIKDVDPYQVEVLEEMKKDKDQLTLITC
DDYDEKTGQWLTRKIYVAERV 
 
Inhibition of Sortase A and its Biological Effects  
The recent emergence of methicillin resistance and multidrug resistance is a major 
concern because conventional antibiotic treatments do not work against such 
‘superbugs’ [56, 70]. Sortase A plays a crucial role in the pathogenesis of Gram-
positive bacteria by modulating the ability of the bacterium to adhere to host tissues 
via the covalent anchoring of adhesins and other virulence factors onto the 
peptidoglycan cell wall. S.aureus mutants lacking Sortase A fail to display surface 
proteins and are defective in the establishment of infections in mouse models. 
Therefore, inhibition of Sortase A is a promising strategy for treatment and 
prevention of Gram-positive bacterial infections [56, 57, 71].  
 
The idea of Sortase A inhibition was explored as early as in 1999 when Ton-That 
and Schneewind demonstrated that methanethiosulphonstes and 
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organomercurials displayed inhibitory effect on Sortase A. It was also observed 
that vancomycin and moenomycin, two antibiotics that are inhibitors of cell wall 
polymerization into peptidoglycan strands, inhibit Sortase A [64, 72]. Several 
natural or chemical compounds ranging from plant extracts, alkaloids, and 
flavonoids have been tested for their abilities to inhibit Sortase A in vitro with limited 
success. Most of these compounds have been evaluated for the ability to inhibit 
Sortase A in vitro by determining the IC50. There are several concerns with in vitro 
inhibition based solely on IC50 values; (a) the mechanism of inhibition needs to be 
completely understood i.e., whether the reaction is reversible or irreversible (b) the 
enzyme kinetics assay parameters have to be evaluated (c) target site validation 
studies have to be performed to determine if the inhibitor binds to the active site of 
the enzyme or elsewhere in the polypeptide (d) the effect of the substrate on the 
inhibition reaction i.e., whether or not there is competitive inhibition (e) the nature 
of enzyme inhibition i.e., the effect of redox action, protein aggregation, pH 
changes on inhibition and (f) the cytotoxic effects (if any) of the compounds. All 
these factors need to be evaluated thoroughly before the inhibitor can be cleared 
for use in humans or animals.  
 
Recent advancements in proteomics and bioinformatics have made it possible to 
identify novel inhibitors of Sortase A. Molecular Dynamic (MD) simulations 
(modeling studies) can predict the binding/active site of the enzyme and also 
facilitate rational design of inhibitors based on their affinities [73, 74]. There are a 
large number of small molecules, drug-like libraries, and robotic automations that 
allow for high-throughput screening [75]. Using synthetic chemistry and medicinal 
chemistry, it is also possible to introduce side chain modifications or remove 
reactive functional groups from the inhibitors such that the affinity of the inhibitor 
to the enzyme to facilitate greater inhibition [76]. Several thousands of compounds 
can be screened virtually and those compounds that display inhibitory potential 
can then be tested in in vitro and in vivo models.  
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Emergence of Methicillin Resistance and Multidrug Resistance 
The emergence of methicillin resistance and multidrug resistance in staphylococci 
has been an important problem both in human and veterinary medicine [77, 78]. 
Virulence genes and antibiotic resistance genes can be transferred between 
isolates of the same species or between different species. This has the potential 
to make a ‘drug-susceptible, avirulent’ strain resistant and highly virulent. There 
are several ways by which this horizontal gene transfer (HGT) is mediated among 
staphylococcal species. (a) Conjugation, mediated by plasmids, is one of the most 
common and frequent methods of HGT. Plasmids carry several antibiotic 
resistance genes and virulence genes that can be transferred to susceptible strains 
upon successful conjugation. (b) Transduction, mediated by bacteriophages, is 
another method by which susceptible strains acquire resistance and virulence 
genes. (c) Transformation, which occurs via uptake of naked (exogenous) DNA 
from the environment [79].  
 
Resistance to methicillin is conferred by the mecA gene. This gene encodes 
penicillin-binding protein 2A (PBP-2A) with reduced affinity for methicillin. The 
mecA gene is contained within a mobile genetic element known as staphylococcal 
cassette chromosome (SCCmec) [80]. Since its first report in 1999, the incidence 
of methicillin resistance in staphylococcal isolates of canine origin has been 
significantly increasing. Methicillin resistance in S.pseudintermedius is of major 
concern because many of the methicillin resistant isolates are also multidrug 
resistant [1, 78]. Treatment options are complicated due to the limited number of 
drug choices to treat infections and the often extremely long and repeated 
treatments needed to clear infections. The problem associated with prolonged use 
of antibiotics, especially in terms of the prudent use of antimicrobials, is the 
emergence of resistance [81].  
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Towards Vaccine Development – Efforts and Reasons for Failure  
As previously described, the increasing prevalence of antibiotic resistance among 
staphylococci is a threat in both human and veterinary medicine  [80, 82]. Non-
antibiotic based alternate treatment strategies to efficiently combat staphylococcal 
infections are urgently needed. Immunological strategies based on vaccine 
development or therapeutic antibodies may have significant roles in the control of 
staphylococcal infections. Vaccines are considered one of the most promising 
approaches especially with the breakthrough of next generation sequencing 
applications which provide novel methods for selecting antigens [22]. Most vaccine 
targets are surface components of staphylococci or soluble virulence determinants 
such as alpha-toxin, Panton-Valentine leukocidins, or superantigenic enterotoxins 
[83].  Much effort has gone into vaccine development for S. aureus, yet none of 
these have been translated into a commercially available protective vaccine. There 
have been several reasons attributed to the failure of an S. aureus vaccine. First 
of all, successful preclinical results obtained with antigens tested in clinical trials 
were likely overestimated by vaccine manufacturers because antigens tested in 
clinical trials provided only partial protection in mice. Also, the protective immunity 
in mice cannot be directly translated into protective immunity in humans. Further, 
vaccines tested in humans to date, since they all targeted single antigens, were 
probably disproportionate to the complex pathogenic mechanisms of the 
bacterium.  
S. aureus produces a wide variety of immune evasion factors that complicate 
vaccine development. In addition, the nature of protective immunity has not been 
clearly understood which in turn has severely limited the ability to interpret both 
preclinical and clinical data. Finally, the vaccines did not contain new generation 
adjuvants, which may be critical in augmenting antibody production and steering 
the T-cell response toward the proper profile of cytokine production [44, 84-86].  
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Recent developments in whole genome sequencing and bioinformatics have made 
it possible to identify novel vaccine candidates in a short span of time by replacing 
time- consuming experimental tasks using in silico prediction steps. This way of 
finding novel antigens has been called reverse vaccinology [87-89]. A successful 
vaccine against staphylococcal infections should be able to elicit three major 
immune responses: 
(i) Humoral immune response i.e., antibodies to directly inhibit bacterial 
viability and/or toxicity 
(ii) Antibodies to facilitate opsonophagocytosis 
(iii) Cell-mediated T-helper 1 (Th1)/Th17 response [84].  
 
However, there are a number of unresolved issues in vaccine development that 
are yet to be elucidated; optimal antigenic target identification, criteria for 
acceptable efficacy, identification of target population, optimal timing of 
immunization strategy and storage to name a few [90]. 
 
 
Concluding Statement 
The objective of this dissertation was to characterize the roles of Protein A and 
Sortase A as potential targets for novel therapeutic approaches against  
S. pseudintermedius infection, along with the analysis of the secretome and 
surface-associated proteins in S. pseudintermedius by mass spectrometry to 
identify novel antigenic and vaccine targets.  
 
It is hypothesized that Protein A is a potent immune evasion factor in  
S. pseudintermedius. Understanding the nature of Protein A and its role in 
pathogenesis and immune evasion could lead to the development of a non-
toxigenic Protein A vaccine that could be useful to treat S. pseudintermedius 
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infection. The increase in methicillin resistance and multidrug resistance among 
staphylococci has sparked interest in the development of novel non-antibiotic 
based treatment strategies to combat this problem. One such attractive target in 
S. pseudintermedius is Sortase A, the transpeptidase enzyme responsible for 
anchoring proteins with an LPXTG motif onto the peptidoglycan cell wall. Many of 
the LPXTG proteins function as potent virulence factors. Inhibition of Sortase A 
could potentially lead to decreased surface expression of all those proteins 
harboring the LPXTG motif, thus rendering the organism less virulent.  
 
The development of a successful vaccine against S. pseudintermedius may 
require a multicomponent vaccine, for which it is essential to identify novel antigen 
and vaccine targets. Also, a good vaccine should include B-cell and T-cell epitopes 
to facilitate the generation of both humoral and cell-mediated immune response, 
thus resulting in protective immunity. This can be achieved by analyzing the 
secretome and surface proteins using mass spectrometry and vaccine prediction 
software.  
 
The immune response to S. pseudintermedius has not been widely studied. A 
deeper knowledge of the virulence factors and immune evasion factors will help 
understand the pathogenesis of S. pseudintermedius. This will aid in the rational 
design and development of vaccines and novel therapeutics, and will ultimately 
pave the way towards treatment and prevention of S. pseudintermedius infections. 
Therefore, I propose using Sortase A inhibition along with a multicomponent 
vaccine containing non-toxigenic Protein A and other potent antigens as a potential 
strategy against antibiotic-resistant S. pseudintermedius infection.  
 
 
This dissertation is organized in a manuscript format. Each chapter is a 
manuscript. Chapter 1 describes Protein A in S. pseudintermedius. In Chapter 2, 
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the molecular basis for Protein A deficiency in the S. aureus strain Wood 46 has 
been explained. As an important addition to this manuscript, the whole genome 
sequence of Wood 46 was published and this is presented in Chapter 3. The 
impact of Sortase A inhibition has been detailed in Chapter 4 followed by the mass 
spectrometric analysis of the secretome and surface associated proteins in S. 
pseudintermedius in Chapter 5.   
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CHAPTER 1.  
Protein A in Staphylococcus pseudintermedius 
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Abstract 
Staphylococcus pseudintermedius is an opportunistic pathogen in dogs and the 
most frequent cause of canine pyoderma. Much of what is known today about  
S. pseudintermedius comes from comparative research with Staphylococcus 
aureus. Protein A, a potent virulence factor in S. aureus is encoded by the spa 
gene. S. pseudintermedius possesses genes seemingly analogous to spa, but the 
expression and the characteristics of their products have not been directly 
determined, and the proteins they encode only share about a fifty percent identify 
with S. aureus Protein A. The purpose of this study was to test isolates from major 
clonal groups for the presence of spa gene orthologs, quantitate their expression 
levels, and to characterize Protein A in S. pseudintermedius.   
 
Results from conventional and quantitative real-time PCR suggest that  
S. pseudintermedius isolates contain genes analogous to spa in S. aureus and the 
mRNA could be quantified.  Isolates representing the major clonal populations in 
the United States and Europe, ST68 and ST71 respectively, bound significant 
amounts of canine IgG and more than isolates with other genetic backgrounds.  
Canine IgG bound to Protein A on  
S. pseudintermedius via its Fc region similar to Protein A from S. aureus. The 
expression profile of spa differed based on the sequence types and was correlated 
to the density of Protein A on the bacterial surface. It was also observed that 
Protein A was secreted during the exponential growth phase. Phagocytosis 
experiments with S. pseudintermedius show that blocking Protein A enhanced 
phagocytosis in whole blood, neutrophils and DH82 canine macrophage-like cell 
line. Taken together, the results demonstrate that  
S. pseudintermedius produces Protein A that shares S. aureus’ ability to bind the 
Fc region of immunoglobulins and may serve as a potential virulence factor by 
evading the host immune system.  
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Introduction 
S. pseudintermedius is the most common species of bacteria isolated from canine 
pyoderma. Recently, this organism has developed widespread resistance to 
methicillin [91-97] . Many methicillin-resistant S. pseudintermedius (MRSP) strains 
are also multidrug resistant. In one study by Sasaki et al., all 18 of the MRSP 
strains detected in their patients were resistant to erythromycin, clindamycin, 
trimethoprim-sulfamethoxazole, and levofloxacin [98]. The emergence of 
antimicrobial resistance has gradually shifted the focus of research in this field to 
searching for prophylactic methods of control for these pathogens. Vaccine 
development, however, requires a deeper understanding of the surface properties 
and virulence mechanisms of the various strains of  
S. pseudintermedius 
 
Several sequence types (STs) of S. pseudintermedius have been described, but 
two in particular have been reported in significantly higher numbers than the rest: 
ST68 in the United States and ST71 in European countries [6, 12, 99]. These two 
sequence types are considered the most dominant and successful clonal 
populations in their respective geographic locations, and the reason for their 
success over other strains has yet to be elucidated.  
 
Staphylococci have numerous defenses that allow evasion of the host immune 
system including immunoglobulin binding proteins such as staphylococcal Protein 
A. Protein A is produced by many species of staphylococci [31]. Within S. aureus 
it is a 40–60 kDa cell-wall protein encoded by the spa gene [49, 50] and secreted 
during exponential growth phase [41-43]. It is synthesized by nearly all S. aureus 
isolates and binds to the Fc and Fab regions of immunoglobulins, [33, 35] inhibits 
opsonophagocytic killing [31, 32, 100] and serves as a B cell superantigen [47, 48, 
101]. Furthermore, marginal zone B cells and B-1 cells undergo, preferentially, 
induced cell death with supraclonal depletion and immune tolerance upon 
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exposure to Protein A [45]. Thus, Protein A may interfere with the efficacy of 
vaccines that depend on opsonophagocytic antibody production by binding to B-
cells and preventing their function [44]. On the other hand, antibodies directed 
against Protein A have protected mice in experimental models of S. aureus 
infection [53-55].  
 
Putative Protein A activity has been correlated with virulence in S. 
pseudintermedius; however, this conclusion was based on a semi-quantitative dot 
blot IgG binding assay, did not take other immunoglobulin-binding proteins into 
consideration or demonstrate the presence of spa genes  [102]. Genome 
sequencing studies have shown that S. pseudintermedius contains genes 
analogous to those encoding S. aureus Protein A as well as genes encoding other 
IgG binding proteins [15]. A putative staphylococcal protein A (spa) gene was 
initially described by Moodley et al. in 2008 in the isolate ED99 [5]. This gene was 
used to develop a species-specific spa typing protocol. The spa gene ortholog in 
ED99 is 1389bp in length and has 68% nucleotide and 55% predicted amino acid 
identity to the homologous gene in the S. aureus reference strain 8325-4 in which 
Protein A was originally described. The predicted protein contained a number of 
functional regions and conserved domains that were previously described in S. 
aureus, including four IgG-binding domains and a polymorphic X-region [5, 15]. 
Lack of IgG-binding domain region B (58 amino acids) partly accounted for the 
shorter protein in S. pseudintermedius ED99 compared to Protein A in S. aureus. 
[5] .  
 
Bannoehr et al. in 2011 suggested that there were two predicted orthologues of S. 
aureus protein A in ED99, SpsP (designated as Spa2) and SpsQ (which encodes 
a full length protein A designated as Spa1) [15]. The spsP gene encodes a protein 
that consists of 377 amino acids in ED99. This protein is 73% identical to SpsQ at 
the amino acid level. It has a predicted N-terminal sequence of 33 amino acids, 
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followed by a repeat region consisting of three predicted IgG-binding domains. 
Each IgG-binding domain consists of 55 amino acids with 78%-85% identity 
between domains. The C-terminal region has a predicted X-region which shares 
63% overall sequence similarity to the X-region of S. aureus.  
 
The spsQ gene encodes a protein that is 462 amino acids in ED99. It also has a 
predicted N-terminal sequence of 33 amino acids, followed by a repeat region 
consisting of four IgG-binding domains. The four IgG-binding domains vary from 
59 amino acids for the first and second, to 55 amino acids for the third, and 52 
amino acids for the fourth domain. They have between 59%-86% identity at the 
protein level. The repeated IgG-binding domains are well conserved between 
SpsP and SpsQ, with 67% to 90% sequence identity in pairwise alignments. The 
C-terminal region consists of a predicted X-region which includes a 77 amino acid-
long repeat sequence (Xr) and a constant region (Xc) with 70% similarity to the X-
region of S.aureus [5].  
 
Whole genome sequencing of several S. pseudintermedius isolates [103] has 
shown that most isolates have a full-length spsQ gene while they may or may not 
harbor the full length spsP gene. It is not known, however, whether or not these 
genes are expressed and produce functional protein in S. pseudintermedius or if 
there are differences in the level of Protein A expression in different strains. The 
purpose of this study was to characterize Protein A in S. pseudintermedius.  In 
order to determine this, the ability of S. pseudintermedius Protein A to bind canine 
IgG and its digestion fragments, Fab and Fc, was determined. Gene expression 
profiles were correlated with surface protein expression. In addition to surface-
associated Protein A, secreted Protein A in S. pseudintermedius was also 
investigated, because the secreted form might function as a potent superantigen.  
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Materials and Methods 
Bacterial Strains and Growth Conditions  
 
S. pseudintermedius clinical isolates (Table 1.1) were used for all experiments. S. 
aureus strain Cowan 1 and the S. pseudintermedius spa negative isolate 57395 ( 
a kind gift from Dr. Vincent Perreten, Institute of Veterinary Bacteriology, Vetsuisse 
Faculty, University of Bern, Bern, Switzerland)  were used as the positive control 
and negative control strains for spa respectively wherever applicable.  The strains 
were selected based on their sequence types. Representatives from the most 
prevalent sequence types in the US and Europe were used in this study. The 
genetic background of the isolates was determined by multilocus sequence typing 
(MLST) [6]. Bacteria from blood agar plates were grown overnight in 5ml of 
Trypticase Soy Broth (TSB, Becton Dickinson, Franklin Lakes, NJ) at 37°C in a 
shaker incubator at 225rpm. Fifty microliters of overnight culture was inoculated 
into 5ml of fresh, sterile TSB and incubated for 3hr at 37°C with shaking to obtain 
log phase cultures (OD600 = 0.4-0.6) which were used for all the experiments 
unless mentioned otherwise.  
 
DNA Extraction and Conventional PCR 
 
Bacterial DNA was extracted from overnight cultures using a commercial kit 
(MoBio Ultra Clean DNA Isolation Kit, MoBio, Carlsbad, CA) according to the 
manufacturer’s protocol. PCR for detection of spsQ gene in clinical isolates was 
performed using the following primers: spa forward 5’-
ATCTCAACCTGCTCCTGATTAC-3’ and spa reverse 5’-
GCATCTTTCGCTTTGTCCATAC-3’. The following cycling conditions were 
performed: initial denaturation at 95°C for 90s, 30 cycles of annealing at 55°C for  
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Table 1.1 Bacterial isolates used in this study along with their sequence type 
and methicillin resistance profile 
Strain Sequence Type Methicillin 
Resistance 
ED99 ST25 S 
07 676c ST29 R 
08 547a ST30 R 
08 1781 ST43 S 
57395 (spsQ negative) ST45 R 
08 1791 ST46 S 
07 1447 ST54 R 
NA47 ST56 S 
NA12 ST64 R 
06 3228 ST68 R 
08 1294 ST68 R 
08 521a ST68 R 
08 1661 ST71 R 
E140 ST71 R 
NA16 ST71 R 
07 5066 ST83 R 
NA45 ST84 R 
KM241 ST93 R 
 
 
 
 
 
 
 
31 
 
30s and extension at 72°C for 1min followed by a final extension at 72°C for 5min. 
PCR products were sequenced (The University of Tennessee Genomics Core 
Facility), aligned and compared using Geneious 9.1.0 (Biomatters, Auckland, New 
Zealand). 
 
RNA Extraction and Quantitative Real-Time PCR 
Total RNA was extracted from log-phase bacterial cultures using a commercial kit 
(MoBio Ultra Clean RNA Isolation kit, MoBio, Carlsbad, CA) according to the 
manufacturer’s protocol. Quantitative reverse-transcriptase PCR (RTqPCR) for 
spsQ was performed using the TaqMan RNA-to-CT 1-Step kit on an ABI StepOne 
PCR System (Applied Biosystems, Foster City, CA) using the primer-probe set : 
5’-/56-FAM/CGCCAAGTT/ZEN/TCGATGAAGCGCAA/3IABkFQ/-3’, 
5’CCGTTACGTTGCTCTTCAGTA-3’, 5’-TAACCAAACACCTACACAACCT-3’. 
The following cycling conditions were performed: 48°C for 30min, 95°C for 10min 
and 40 cycles of 95°C for 15s and 60°C for 1min. qPCR data were analyzed by 
the ΔΔCT method and normalized against 16S rRNA as the endogenous control 
as previously described [104].  
 
Preparation of Canine Fab and Fc Fractions from Canine IgG and Biotin 
Conjugation  
 
Lyophilized canine IgG (IR-DG2-GF, Innovative Research, Novi, MI) was dissolved 
in sterile PBS (pH 7.2). Canine Fab and Fc fractions were prepared using a kit 
according to the manufacturer’s instructions (Pierce Fab preparation kit, Thermo 
Scientific, Waltham, MA). Briefly, 1mg/ml of canine IgG equilibrated in digestion 
buffer was added to papain (immobilized on beads) and incubated for six hours at 
32 
 
37°C with shaking. Enzyme treated-IgG was then added to a Protein A column to 
bind Fc fragments. Unbound Fab fragments were collected and Fc fragments were 
eluted and immediately adjusted to neutral pH. All fragments were equilibrated in 
PBS (pH 7.2). 
 
Fc and Fab fragments prepared above and whole canine IgG were conjugated to 
biotin (EZ-link NHS-PRG4-Biotin, No-Weigh Format, ThermoFisher Scientific, 
Waltham, MA) according to the manufacturer’s protocol. Two milligrams each of 
whole IgG, Fab and Fc were biotinylated. Unbound biotin was removed and the 
fractions were equilibrated in PBS by ultrafiltration, and stored at 4°C until used. 
 
Canine IgG Binding Assay 
 
One milliliter of log phase bacterial culture was centrifuged at 10,000xg for 1min. 
The bacteria were washed and suspended in 1ml of PBS and incubated with 100μl 
of whole canine IgG (described above) at concentrations of 10μg/ml, 100μg/ml or 
1000μg/ml for 30min at room temperature. The cells were washed twice with PBS 
and incubated with 100μl of 1:100 dilution of goat anti-canine IgG (H+L)-FITC 
conjugate (Southern Biotech, Birmingham, AL) for 30min at room temperature in 
the dark. For the binding assay with canine Fab and Fc fractions, log phase 
bacteria were incubated with 2μg/ml biotin-conjugated whole IgG, Fab or Fc 
prepared previously at room temperature for 30min. Bacteria were washed as 
before and incubated with 1:500 dilution of avidin-FITC conjugate (Sigma-Aldrich, 
St. Louis, MO) at room temperature for 30min in the dark. The cells were washed 
and the amount of binding was determined by flow cytometry.  
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Protein A Binding Assay 
One milliliter of log phase bacterial culture was centrifuged at 10,000xg for 1min. 
The pellets were washed twice with PBS and resuspended in 1ml PBS and 
incubated with 100μl of 1:100 dilution of chicken anti-Protein A-FITC conjugate 
(Gallus Immunotech, Cary, NC) at room temperature for 30min in the dark. 
Bacteria were washed again and the amount of binding was determined by flow 
cytometry.  
 
Competitive Binding Assay 
 
One milliliter of log phase bacterial culture was centrifuged at 10,000xg for 1min. 
The pellet was washed and suspended in 1ml PBS and incubated with 100μl of 
1:100 dilution of chicken anti-Protein A antibody (Gallus Immunotech, Cary, NC) 
for 30min at room temperature. The bacteria were washed as previously 
described. One hundred microliter of 2µg/ml of biotin-conjugated canine Fc was 
added and incubated at room temperature for 30min. After incubation, the bacteria 
were washed and a 1:500 dilution of avidin-FITC conjugate (Sigma-Aldrich, St. 
Louis, MO) was added and incubated for an additional 30min in the dark. Bacteria 
were washed again and the amount of binding was determined by flow cytometry. 
 
Enzyme Linked Immuno Sorbent Assay 
Secreted Protein A in log-phase culture supernatants was measured using an 
antigen capture ELISA. Briefly, 96-well flat bottom, costar plates (Corning Inc., 
Corning, NY) were coated overnight at 4°C with 1μg/ml of mouse monoclonal anti-
protein A antibody clone SPA-27 (Mouse IgG1 isotype, Sigma-Aldrich, St. Louis, 
MO,) in PBS. Bacterial supernatant containing secreted Protein A was added and 
incubated at 37°C for 1 hour. Bound antigen was detected using a 1:500 dilution 
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of HRP-conjugated chicken anti-protein A antibody (Gallus Immunotech, Cary, 
NC) followed by addition of 100μl/well of tetramethylbenzidine (TMB) substrate 
(Sigma-Aldrich, St. Louis, MO). Plates were washed in between each step with 
PBS containing 0.05% polysorbate-20 using an ELX405 auto plate washer (BioTek 
Instruments Inc., Winooski, VT). The reaction was stopped by adding 50μl/well of 
0.18M sulfuric acid. The optical density was measured at 450nm using an ELX800 
Universal Microplate Reader (BioTech Instruments Inc. Winooski, VT). 
 
Labeling of Bacteria with pHrodoTM Red Amine-Reactive Label 
 
Bacterial isolate 08-1661 (ST71) was labeled with pHrodo Red, succinimidyl ester 
(pHrodoTM Red, SE, ThermoFisher Scientific, Waltham, MA) according to the 
manufacturer’s instructions with minor variations. Briefly, 1mg of the pHrodoTM Red 
SE was dissolved in 150μl of dimethyl sulfoxide (DMSO) to make a stock solution 
of 10.2mM. 5ml of overnight bacterial culture was centrifuged 10,000g for 5 min 
and the pellet was washed twice with phosphate buffered saline (PBS, pH 7.2). 
One milligram of the pellet was resuspended in 750μl of fresh sodium bicarbonate 
buffer, pH 8.5. The prepared dye was diluted into the bacterial suspension at a 
final concentration of 1mM. The tubes were incubated at room temperature for 60 
min in the dark with gentle rocking. After incubation, the cells were washed with 
750μl of Hank’s balanced salt solution (HBSS, ThermoFisher Scientific, Waltham, 
MA) by centrifugation at 15,000g for 1min. The bacterial pellet was resuspended 
in 1ml of 100% methanol (Sigma-Aldrich, St. Louis, MO). Aggregates, if any, were 
removed by gently vortexing. The bacteria were centrifuged again at 15,000xg for 
1min to remove the methanol. Finally, the labeled bacteria were resuspended in 
500μl of HBSS and stored in aliquots at -80°C until use.  
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Whole Blood Phagocytosis Assay 
A pH-sensitive dye, pHrodo Red, which fluoresces only in the acidic environment 
of the phagolysosome was used to label bacteria in order to effectively visualize 
phagocytosis and distinguish phagocytosed bacteria from those that are merely 
adhered to the cell surface.  
Fresh blood was collected in heparinized tubes from healthy dogs following an 
approved IACUC protocol. Briefly, 100μl of blood was mixed with an equal volume 
of pHrodoTM Red-labeled bacteria (containing 5X105 bacteria) and incubated at 
37°C for 30min to facilitate phagocytosis. Control tubes containing all components 
were incubated on ice for the same duration. After 30 min, phagocytosis was 
stopped by addition of ice-cold PBS containing 5mM EDTA. The cells were washed 
by centrifugation at 5000xg for 10min, suspended in 2ml of RBC lysing buffer 
(Sigma-Aldrich, St. Louis, MO) and incubated at 37°C for 20min. The lysed RBCs 
were removed by centrifugation. The pellet was washed twice with PBS and the 
amount of phagocytosis was determined by flow cytometry. The same assay was 
performed after isolating neutrophils from whole blood using a method described 
previously [105] and the results were compared. .  
Phagocytosis in DH82 Cells 
The canine macrophage-like cell line, DH82, was obtained from the American Type 
Culture Collection (ATCC, CLR-10389), propagated and maintained in Eagle’s 
Minimum Essential Medium (EMEM, Quality Biological Inc., Gaithersburg, MD) 
containing 15% heat-inactivated fetal bovine serum (Sigma Aldrich, St. Louis, MO) 
and 1% penicillin/streptomycin/amphotericin-B mixture (Lonza, Walkersville, MD). 
Cells were grown to confluency, trypsinized and seeded into 24-well costar tissue 
culture plates (Corning Inc., Corning, NY) at a density of 1x106 cells per well and 
allowed to adhere. pHrodoTM Red-labeled bacteria were added at an MOI of 100 
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and incubated for 30min at 37°C to facilitate phagocytosis. A control plate with all 
the components was incubated on ice for the same duration. After incubation, 
phagocytosis was stopped by the addition of ice cold PBS containing 5mM EDTA. 
The plate was allowed to sit for 5 min at room temperature. The PBS-EDTA was 
gently aspirated and the adherent cells were harvested by standard trypsin 
treatment for 5 min at 37°C. The contents from each well were transferred into a 
vial and centrifuged at 5000g for 10 min. Cells were washed twice and suspended 
in 1ml of PBS and analyzed by flow cytometry. Each sample was run in triplicate 
and analyzed individually. Non-infected cells served as negative control to set the 
cut-off for the discrimination of pHrodoTM Red-negative and -positive cells, and the 
cells incubated on ice served as control to determine the percentage of 
phagocytosis. 
 
Flow Cytometry 
 
Binding experiments with canine IgG, anti-Protein A antibody and phagocytosis 
assay using labeled bacteria were performed by flow cytometry. The amount of 
binding or phagocytosis was determined by measuring the fluorescence using an 
Attune acoustic focusing cytometer (Applied Biosystems, Foster City, CA) at 
excitation/emission wavelengths of 488/519 nm for green fluorescence and 
560/585 nm for red fluorescence. Data were acquired in linear mode for forward 
and side scatter and logarithmic mode for fluorescence. For each sample, 10,000 
events were measured. 
Statistical Analysis 
 
A one-way ANOVA and multiple comparisons using Tukey’s honest significant 
difference were performed to test if there was a significant difference in the 
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expression of spsQ among bacterial isolates, and also to determine if there was a 
significant difference in the amount of surface-expressed Protein A, secreted 
Protein A and percentage of phagocytosed bacteria. Each experiment was 
repeated at least three times and a p-value of <0.05 was considered significant. 
All analyses were conducted using the GraphPad Prism software (Version 7, 
GraphPad Software Inc, La Jolla, CA). 
 
Results 
S. pseudintermedius Contains Genes Analogous to spa in S. aureus 
 
Whole genome sequences of isolates representing MLST sequence types ST68 
(06-3228), ST71 (08-1661) and ST84 (NA45) were examined for the spa gene 
ortholog [103]. Gene-specific primers were designed from a consensus sequence 
after performing multiple sequence alignment, to amplify both the partial and full-
length spsQ gene. The PCR results showed that all but one isolate (the spsQ 
negative isolate 57395) examined in this study contained the spsQ gene. Further, 
sequence analysis of the spsQ gene from isolates representing ST68 and ST71 
showed that they share 96% identity with that of the previously published spa gene 
from ED99, while the spsQ gene from NA45 shared about 53% identity with that 
of ED99. The spsQ gene sequences from 06-3228, 08-1661 and NA45 are 
available in GenBank [103]. 
 
Expression of spsQ Gene in S. pseudintermedius  
 
Reverse transcriptase qPCR was used to analyze the expression of spa in various 
S. pseudintermedius isolates. The results showed that expression profiles of spsQ 
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varied among sequence types. Isolates representing ST68 had lower expression 
(approximately 1.5 log reduction) compared to isolates from ST71, but in general, 
ST68 and ST71 isolates had higher spsQ expression than isolates from other 
sequence types. The spsQ expression levels in isolates NA12, NA45 and KM241 
could not be quantified because they were below the detection limits of the assay. 
Isolate 57395, which was negative for spsQ, did not produce detectable amounts 
of spsQ mRNA. spsQ expression levels were normalized against 16S rRNA as the 
endogenous control and the results were expressed as fold change in mRNA 
levels using the ΔΔCT method. To ensure equal amplification efficiencies of the 
target and control genes, four 10-fold serial dilutions of the target RNA were tested. 
The efficiencies of both the target gene and the endogenous control were 
comparable (Figure 1.1).  
 
Cell Wall-Associated Protein A in S. pseudintermedius 
 
The density of surface-anchored Protein A in S. pseudintermedius was determined 
by flow cytometry. Since there was no commercially available antibody against 
Protein A from S. pseudintermedius, FITC conjugated anti-Protein A antibody 
raised against S. aureus Protein A was used for this experiment. The amount of 
binding was normalized against S. aureus Cowan 1 and expressed as percentage 
bound relative to positive control. The results showed that isolates representing 
ST68 and ST71 bound significantly more antibody compared to isolates 
representing other sequence types suggesting that both ST68s and ST71s 
express a higher density of Protein A on their  
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Figure 1.1 Expression levels of spsQ.  
qPCR was performed to measure the amount of spsQ mRNA in log phase bacterial 
cells. Relative gene expression was calculated using the ΔΔCT method and 
expressed as fold change. 16S rRNA was used as the endogenous control. The 
values represent the average from three independent experiments. (*P<0.05 was 
considered significant).  
#The spsQ mRNA levels in isolates NA12, NA45 and KM241were below the detection limits of the 
assay. 
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surface. Isolates 06-3228, 08-1294 and 08-521a (representing ST68) bound 
34.47%, 20.94% and 27.54% of the labeled antibody respectively; while isolates 
08-1661, E140 and NA16 (representing ST71) bound 40.77%, 29.92% and  
38.26% of the labeled antibody respectively, relative to Cowan 1 (Figure 1.2). 
Between isolates from ST68 and ST71, it was found that ST71 isolates bound a 
higher percentage of the antibody, suggesting that these isolates may have a 
higher density of Protein A on the surface. Since the antibody raised against 
Protein A in S. aureus recognizes and binds to Protein A on  
S. pseudintermedius, Protein A in these two species apparently share epitopes, 
however, differences between the two species may affect relative antibody 
reactivity. 
 
Canine IgG Reacts with Protein A on the Surface of S. pseudintermedius and 
Binds to Protein A via its Fc Region 
 
To determine if canine IgG binds to Protein A on the surface of  
S. pseudintermedius, a binding experiment with canine IgG was performed. 
Canine IgG was diluted 10-fold from 10μg/ml to 1mg/ml and incubated with log 
phase cultures of various strains of S. pseudintermedius. A dose response was 
observed for binding with increasing amounts of canine IgG (Figure 1.3), 
suggesting that canine IgG recognizes and binds to Protein A on  
S. pseudintermedius. 
 
Isolates representing various sequence types (listed in Table 1.1) were reacted 
with 100μg/ml of canine IgG. It was observed that isolates representing ST68 and 
ST71 bound significantly more canine IgG than isolates from other sequence types 
suggesting that they may have a higher density of cell-wall associated Protein A 
on their surface (Figure 1.4).  
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Figure 1.2 Protein A on the surface of S. pseudintermedius.  
The density of cell wall-associated Protein A in various strains of  
S. pseudintermedius was measured using FITC-conjugated anti-Protein A 
antibody by flow cytometry. The values represent the average from three 
independent experiments. (*P<0.05 was considered significant).  
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Figure 1.3 Binding of canine IgG to Protein A on S. pseudintermedius (dose-
response).  
A dose-response effect observed when varying concentrations of canine IgG 
ranging from 10μg/ml-1000μg/ml was treated with S. pseudintermedius. The 
values represent average from three independent experiments. (P<0.05 was 
considered significant).  
 
 
 
 
 
 
 
 
 
43 
 
 
Figure 1.4 Canine IgG recognizes and binds to Protein A on  
S. pseudintermedius.  
Isolates representing various sequence types of S. pseudintermedius were 
reacted with 100μg/ml of canine IgG. The amount of binding was determined by 
flow cytometry and expressed as percentage bound relative to the positive control 
S. aureus Cowan 1 strain. The values represent average from three independent 
experiments. (*P<0.05 was considered significant).  
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After determining that canine IgG recognizes and binds to Protein A on  
S. pseudintermedius, the next step was to examine which fraction of canine IgG 
specifically binds to Protein A. Protein A in S. aureus binds to IgG primarily via its 
Fc region [54]. It was hypothesized that Protein A in S. pseudintermedius also 
binds IgG via its Fc region. In order to test this, canine IgG was digested with 
papain to generate Fab and Fc fragments and reacted with bacteria. Two 
microgram of each of the fragments, Fab and Fc, along with whole IgG were 
reacted with various strains of S. pseudintermedius. The results showed that 
Protein A in S. pseudintermedius binds to canine IgG via its Fc region (Figure 1.5). 
Data for isolates representing the predominant sequence types 06-3228 (ST68), 
08-1661 (ST71), NA12 (ST64) and NA45 (ST84) have been presented.  
 
Anti-Protein A Antibody Inhibits the Binding of Canine Fc Fragment to  
S. pseudintermedius 
 
In order to determine whether anti-Protein A antibody (raised in chickens against 
S. aureus Protein A) binds to Protein A on the surface of S. pseudintermedius, a 
competitive inhibition assay was performed. Bacterial cells were incubated with 
excess of unlabeled chicken anti-Protein A antibody prior to adding biotin-
conjugated canine Fc. Anti-Protein A antibody competitively inhibited the binding 
of canine Fc as determined by a decrease in fluorescence when detected using 
flow cytometry (Figure 1.6). A titration experiment was performed to determine the 
optimal dilution of both the anti-Protein A antibody and the canine Fc fraction that 
results in at least 50% reduction in binding of canine Fc. Data for isolates from  
strains 06-3228 (ST68), 08-1661 (ST71), NA12 (ST64) and NA45 (ST84) have 
been presented in (Fig 1.6). Since isolates NA12 and NA45 showed very little 
binding to canine IgG and anti-Protein A antibody (Figure 1.2 and Figure 1.4), 
these isolates were not expected to show any inhibition (Figure 1.6).  
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Figure 1.5 Protein A binds to canine IgG primarily via its Fc region.  
S. pseudintermedius isolates were treated with IgG and its papain digestion 
fragments, Fab and Fc. The amount of binding was determined by flow cytometry. 
The values represent average from three independent experiments. (*P<0.05 was 
considered significant).  
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Figure 1.6 Binding of anti-Protein A antibody prevents the binding of canine 
Fc to Protein A on S. pseudintermedius.  
Bacterial isolates were incubated with an excess of chicken anti-Protein A antibody 
prior to the addition of canine Fc. There was at least 50% reduction in the binding 
of canine Fc because of anti-Protein A antibody binding. The values represent 
average from three independent experiments. (*P<0.05 was considered 
significant). 
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This further strengthened the fact that S. pseudintermedius expresses Protein A 
on its surface and is recognized by the commercially available anti-Protein A 
antibody.  
 
Protein A in Bacterial Culture Supernatant 
 
S. aureus isolates secrete Protein A into the culture supernatant during log phase 
[41, 42]. In order to determine if S. pseudintermedius isolates also secrete Protein 
A during log phase, a capture ELISA was used to measure the amount of Protein 
A in bacterial culture supernatants. Log phase culture supernatants from various 
bacterial isolates were tested. The results showed that isolates representing ST68 
and ST71 secreted higher amounts of Protein A into the culture supernatant 
compared to isolates from other sequence types. S.aureus Cowan 1, used as the 
positive control, secreted 23.1ng/ml of Protein A. Isolates 06-3228, 08-1294 and 
08-521 secreted between 0.98ng/ml-2.19ng/ml of Protein A. Isolates 06-1661, 
E140 and NA16 secreted between 3.45ng/ml-9.94ng/ml of Protein A (Figure 1.7). 
Among isolates from ST68 and ST71, a significant difference was observed in the 
amount of secreted Protein A, with ST71s secreting higher amounts than ST68s. 
As expected, isolate 57395, which was negative for the spsQ gene by both 
conventional and quantitative real-time PCR did not produce detectable amounts 
of Protein A. The lower limits of detection and quantification of the assay were 
0.125ng/ml and 0.3ng/ml respectively. Taken together, these results suggest that 
S. pseudintermedius not only expresses Protein A on its surface but also secrets 
it into the culture supernatant during log phase. 
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Figure 1.7  Production of extracellular Protein A in S.pseudintermedius.  
The amount of extracellular Protein A was measured using an antigen-capture 
ELISA. Commercially available Protein A from S.aureus was used to generate the 
standard curve. The values represent the average from three independent 
experiments. (*P<0.05 was considered significant). 
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Binding of Anti-Protein A Antibody makes S. pseudintermedius more 
Susceptible to Phagocytosis in Whole Blood, Canine Neutrophils and DH82 
Cells  
 
In order to determine if Protein A in S. pseudintermedius can function as an 
immune evasion factor, phagocytosis was performed using canine whole blood, 
neutrophils and DH82 canine macrophage-like cells. S. pseudintermedius isolate 
08-1661 was labeled with a pH-sensitive dye, pHrodoTM Red which enables easy 
visualization of phagocytosis. The labeled bacteria fluoresce in the acidic 
environment of phagosomes, allowing the differentiation and visualization of 
phagocytosed bacteria from those that are merely adhered to the cell surface.  
 
The percentage of phagocytosis after 30min at 37°C in whole blood, neutrophils 
and DH82 macrophage-like cells was 57.8%, 54.6% and 44.3% respectively 
compared to the control which was incubated on ice for the same duration. To test 
the involvement of Protein A in preventing phagocytosis, labeled bacteria were 
pre-incubated with 100μg/ml of either chicken anti-Protein A antibody or canine 
IgG before the start of phagocytosis. With both canine blood and neutrophils, pre-
incubation of the bacteria with anti-Protein A antibody enhanced phagocytosis by 
at least 10%, although this difference was not significant (Figure 1.8 and Figure 
1.9). In DH82 cells however, phagocytosis was significantly enhanced by 17.8% in 
the presence of anti-Protein A antibody (Figure 1.10) compared to the control 
without anti-Protein A antibody. Canine IgG was also used in the experiment, but 
it did not have any effect on phagocytosis. The duration for phagocytosis was 
determined by a time course experiment and 30min was found to be optimal as 
with previous studies involving S. aureus (Figure 1.11) [106, 107].  
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Figure 1.8  Phagocytosis in whole blood.  
The involvement of Protein A in immune evasion was demonstrated by 
phagocytosis using pHrodoTM Red-labeled 08-1661 in whole blood. Incubation of 
bacteria with anti-Protein A antibody enhanced phagocytosis. The values 
represent average from three independent experiments. (*P<0.05 was considered 
significant). 
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Figure 1.9  Phagocytosis in neutrophils.  
The involvement of Protein A in immune evasion was demonstrated by 
phagocytosis using pHrodoTM Red-labeled 08-1661 in neutrophils. Incubation of 
bacteria with anti-Protein A antibody enhanced phagocytosis. The values 
represent average from three independent experiments. (*P<0.05 was considered 
significant). 
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Figure 1.10  Phagocytosis in DH82 canine macrophage-like cell line.  
The involvement of Protein A in immune evasion was demonstrated by 
phagocytosis using pHrodoTM Red-labeled 08-1661 in DH82 canine macrophage-
like cell line. Incubation of bacteria with anti-Protein A antibody significantly 
enhanced phagocytosis. The values represent average from three independent 
experiments. (*P<0.05 was considered significant). 
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Figure 1.11  Phagocytosis of pHrodoTM Red-labeled 08-1661.  
Time-course experiment to demonstrate phagocytosis at 37°C and a control 
experiment at 0°C.  
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Taken together, these results suggest that Protein A in S. pseudintermedius could 
function as an immune evasion factor similar to Protein A in S. aureus, and prevent 
bacteria from being opsonized and phagocytosed.  
 
Discussion 
 
Protein A is a widely studied virulence and immune evasion factor. Nearly all  
S. aureus isolates are known to produce Protein A [31]. It is expressed on the 
peptidoglycan cell wall and is also secreted into the bacterial culture supernatant 
during exponential growth phase [41-43, 49, 108]. One of the most important 
features of Protein A is its ability to bind IgG via its Fc region, thereby preventing 
opsonization and phagocytosis [33-35]. This helps the bacteria evade the host 
immune response, leading to persistent infections [32, 36, 37, 100].  
S. pseudintermedius, the canine pathogen implicated as the causative agent of 
pyoderma also contains genes predicted to encode Protein A [7, 15]. Protein A in 
S. pseudintermedius has not been previously studied or characterized. 
 
In this study, the presence of cell-wall anchored Protein A was measured by flow 
cytometry. It was found that Protein A is a component of the cell wall of most of the 
isolates tested in this study (Fig 1.2). It was also found that canine IgG was able 
to react with Protein A on the surface of S. pseudintermedius. Protein A on S. 
pseudintermedius bound to canine IgG via its Fc fragment (Fig 1.4 and Fig 1.5) 
suggesting that it may escape phagocytosis and serve as an immune evasion 
factor. It should be noted that the anti-Protein A antibody used in this study is raised 
against S. aureus Protein A. Also, canine IgG used in this study could be binding 
the bacterial surface via its Fab region. In fact, isolate 57395 which was negative 
for the spa gene by conventional PCR showed some binding to anti-Protein A 
antibody. Since this antibody is raised against S. aureus  
55 
 
Protein A, there is a possibility that it reacts with other surface proteins, particularly 
immunoglobulin binding proteins like Sbi, besides Protein A on the surface of S. 
pseudintermedius. This is true in the case of S. aureus, where spa deletion 
mutants have been shown to bind with anti-Protein A antibody [109-111]. Isolates 
from the dominant clonal populations in the United States and Europe, ST68 and 
ST71, bind more IgG and have a higher density of Protein A on their surface than 
isolates of other STs. This property could explain why isolates from ST68 and 
ST71 are so successful in the population compared to other sequence types. The 
presence of extracellular Protein A in S. pseudintermedius suggests that it could 
also function as a superantigen. Phagocytosis experiments with whole blood, 
neutrophils and DH82 macrophage-like cells indicate that blocking bacterial 
surface Protein A with anti-Protein A antibody makes it more susceptible to 
phagocytosis. Taken together, the results suggest that Protein A in S. 
pseudintermedius may share common features with its S. aureus counterpart, and 
serve as a potent virulence factor.   
 
Vaccine studies with S. aureus have indicated that a multivalent vaccine with 
different epitopes would probably work best [44, 84, 112]. Keeping the same 
factors in mind, the successful development of a vaccine against  
S. pseudintermedius would involve identifying antigenic targets representative of 
a wide variety of strains and sequence types. Understanding the nature of surface 
proteins and their role in virulence and pathogenesis is critical for vaccine 
development against S. pseudintermedius infection.  
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Abstract 
Protein A in Staphylococcus aureus is encoded by the spa (staphylococcal protein 
A) gene and binds to immunoglobulin (Ig).  The S. aureus strain Wood 46 has been 
variously reported as Protein A-deficient and/or spa negative and used as a control 
in animal models of staphylococcal infections. The results of this study indicate 
that Wood 46 has normal spa expression but transcribes very low levels of the srtA 
gene which encodes the Sortase A (SrtA) enzyme. This is consistent with unique 
mutations in the srtA promoter. In this study, a low level of Sortase A explains 
deficient anchoring of proteins with an LPXTG motif, such as Protein A, fibrinogen-
binding protein and fibronectin-binding proteins A and B on to the peptidoglycan 
cell wall. The activity of secreted Protein A is an important consideration for use of 
Wood 46 in functional experiments and animal models.  
 
Introduction  
Protein A produced by S. aureus is a potent virulence factor and immune-
modulator [31, 113-116]. It is a 40–60 kDa cell-wall protein encoded by the spa 
gene [49, 50]. It is synthesized by nearly all S. aureus isolates and binds to the Fc 
and F(ab)2 regions of immunoglobulins [33, 35], prevents opsonophagocytic killing 
[31, 32, 100] and serves as a B-cell superantigen [47, 48, 101]. Furthermore, 
marginal zone B cells and B-1 cells undergo, preferentially, induced cell death with 
supraclonal depletion and immune tolerance upon exposure to Protein A [45]. 
Thus, Protein A may interfere with vaccine efficacy that depends on 
opsonophagocytic antibody production by binding to B-cells and preventing their 
function. The S. aureus strain Wood 46 had been considered spa negative and 
Protein A-deficient. For this reason, it was used as a negative control in studies 
involving S. aureus virulence [31, 117-123]. There is evidence that Wood 46 
produces extracellular Protein A during exponential growth phase and steady state 
[119]. This has been demonstrated indirectly by immunoglobulin binding 
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experiments [119]. Extracellular Protein A has also been isolated from Wood 46 
using IgG Sepharose chromatography, although the amount of putative Protein A 
recovered from  Wood 46 is lower compared to S. aureus strain Cowan 1, a high 
producer of Protein A [118, 119]. S.aureus produces a second immunoglobulin-
binding protein (Sbi), which is also capable of binding to the Fc portion of IgG 
similar to Protein A and protects the bacteria against innate immune responses 
[109].  
 
Sortase A (SrtA) is a transpeptidase commonly produced by Gram-positive 
bacteria. It has specificity for proteins with an LPXTG motif and cleaves between 
the threonine (T) and glycine (G) residues to form an acyl enzyme intermediate 
that is relieved by the nucleophilic attack of the amino group in the pentaglycine 
cross bridge of the peptidoglycan precursor[62]. Modified proteins are 
subsequently incorporated into the peptidoglycan cell wall and displayed on the 
surface [56, 62-64, 66, 108, 124]. S. aureus isolates encode approximately 17-21 
surface proteins with an LPXTG motif [70, 115, 125]. These include Protein A, 
fibrinogen-binding proteins - clumping factors A and B (Clf A/B) and fibronectin 
binding proteins (FnBP A and FnBP B) that function as potent virulence factors 
[126]. S. aureus mutants lacking SrtA fail to covalently attach proteins with an 
LPXTG motif onto their cell wall, and are thus less virulent than their wild-type 
counterparts. They do not form abscess lesions in organs or cause bacteremia in 
mouse models [70, 74]. In this study, the reason for Protein A deficiency on the 
surface of Wood 46 was investigated and the defective expression of spa and srtA 
genes encoding functional proteins was examined as a possible cause. 
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Materials and Methods 
Bacterial Strains and Growth Conditions 
 
S. aureus strain Wood 46 (ATCC 10832), Seattle 1945 (ATCC 25923) and Cowan 
1 (ATCC 12598) were obtained from the American Type Culture Collection. The 
S. aureus Newman strain and its corresponding spa and sbi mutants (Newman 
WT, Newman sbi::Emr, Newman spa::Kar and Newman sbi::Emr spa::Kar) were a 
kind gift from Drs. Tim Foster and Joan Geoghegan (Department of Microbiology, 
Trinity College Dublin) [109]. Bacteria were grown overnight in Trypticase Soy 
Broth (TSB, Becton Dickinson, Franklin Lakes, New Jersey) at 37°C in a shaker 
incubator and diluted 1:50 in fresh TSB to initiate log-phase cultures.  
 
DNA Extraction and Conventional PCR 
 
Bacterial DNA was extracted from overnight cultures using a commercial kit 
(MoBio Ultra Clean DNA Isolation Kit, MoBio, Carlsbad, CA) according to the 
manufacturer’s protocol. PCR for spa, srt A and the -35 regulatory region was 
performed using primers listed in Table 2.1. The following cycling conditions were 
performed: initial denaturation at 95°C for 90s, annealing at 55°C for 30s and 
extension at 72°C for 1min (30 cycles), and a final extension at 72°C for 5min. PCR 
products were sequenced (The University of Tennessee, Genomics Core Facility) 
and the sequences of spa, srtA and the regulatory region in all isolates were 
aligned and compared using Geneious (version 9.1.6) (Biomatters, Auckland, New 
Zealand). 
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RNA Extraction and Quantitative Real-Time PCR 
Total RNA was extracted from log phase bacterial cultures using a commercial kit 
(MoBio Ultra Clean RNA Isolation kit, MoBio, Carlsbad, CA) according to the 
manufacturer’s protocol. Quantitative Real-Time PCR (qPCR) for spa and srt A 
were performed using the TaqMan RNA-to-CT 1-Step kit on an ABI StepOne PCR 
System (Applied Biosystems, Foster City, CA). The primers and probe used for the 
qPCR are listed in Table 2.1.  The following cycling conditions were performed: 
48°C for 30min, 95°C for 10min, followed by 40 cycles of 95°C for 15s and 60°C 
for 1min. qPCR data were analyzed by the ΔΔCT method and normalized against 
16S rRNA as the endogenous control as previously described [104]. 
 
Protein A ELISA 
Secreted Protein A in culture supernatants was measured using an antigen 
capture ELISA. Briefly, 96-well Costar plates (Corning Inc, Corning, NY) were 
coated with 1μg/ml of mouse monoclonal anti-protein A antibody clone SPA-27 
(Sigma-Aldrich, St. Louis, MO) in PBS pH 7.2. Bacterial supernatant was added 
and incubated at 37°C for 1 hour. Bound antigen was detected using a 1:500 
dilution of HRP-conjugated chicken anti-protein A antibody (Gallus Immunotech, 
Cary, NC) followed by addition of 100μl/well of tetramethylbenzidine (TMB) 
substrate (Sigma-Aldrich, St. Louis, MO). Plates were washed in between each 
step with PBS containing 0.05% polysorbate-20 using an ELX405 auto plate 
washer (BioTek Instruments Inc., Winooski, VT). The reaction was stopped by 
adding 50μl/well of 0.18M sulfuric acid.  The optical density was measured at 
450nm using an ELX800 Universal Microplate Reader (BioTech Instruments Inc.  
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Table 2.1 List of primers used in this study 
Gene Primers Reference 
spa 
(conventional 
PCR) 
F 5’-ATCTGGTGGCGTAACACCTG-3’ 
R 5’-CGCTGCACCTAACGCTAATG-3’ 
This study 
srtA 
(conventional 
PCR) 
F 5’-AAGCGTTTCGTTATTTGAATGC-3’ 
R 5’-TCGTCATTGCTACCTCATACC-3’ 
This study 
spa (qPCR) 5’-/56-
FAM/TTTGTCAGC/ZEN/AGTAGTCGCGTTT
GC/3IABkFQ/-3’ 
5’-ATGTCGTTAAACCTGGTGATACA-3’ 
5’-GGTTTGCTGGTTGCTTCTTATC-3’  
This study 
srtA (qPCR) 5’-/56-
FAM/AGCAAGCTA/ZEN/AACCTCAGATTCC
GAAAGA/3IABkFQ/-3’ 
5’-GAACAGGCGAGTAAAGACAATAAG-3’ 
5’-GGTCCTGGATATACTGGTTCTTT-3’  
This study 
16S (qPCR) 5’-/56-
FAM/CCGGCAGTC/ZEN/AACTTA/3IABkFQ/-
3’ 
5’-CACCTTCCTCCGGTTTGTCA-3’ 
5’-CCCTTGAACTTAGTTGCCATCATTC-3’ 
[104] 
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Winooski, VT). Commercially available S. aureus Protein A (Thermo Scientific, 
Rockford, IL) was used to generate the standard curve. 
 
Flow Cytometry to Measure Surface-Expressed Protein A, Fibrinogen-
Binding Protein and Fibronectin-Binding Protein  
 
One milliliter of log phase bacterial cells were washed and incubated with either 
no conjugate (NC, negative control), 2μg/ml of chicken anti-protein A FITC 
conjugate (Gallus Immunotech, Cary, NC), 1μg/ml human fibrinogen FITC 
conjugate (Zedira GmbH, Darmstadt, Germany) or 1μg/ml bovine fibronectin 
HiLyte Fluor TM 488 conjugate (Cytoskeleton Inc., Denver, CO) for 30 min at room 
temperature in the dark. Excess conjugate was removed by washing and the 
amount of binding determined by measuring fluorescence using an Attune acoustic 
focusing cytometer (Applied Biosystems, Foster City, CA) at excitation/emission 
wavelengths of 488/519 nm. Data were acquired in linear mode for forward and 
side scatter and logarithmic mode for fluorescence. For each sample, 10,000 
events were measured. 
 
Statistical Analysis 
 
A one-way ANOVA and multiple comparisons using Tukey’s honest significant 
difference were performed to test if there was a significant difference in the 
expression of spa and srt among bacterial isolates, and also to determine if there 
was a significant difference in the amount of surface-expressed Protein A, 
fibrinogen-binding protein and fibronectin-binding protein. Each experiment was 
repeated at least three times and a p-value of <0.05 was considered significant. 
All analyses were conducted using the IBM SPSS Statistics for Windows, Version 
22.0 (IBM Corp, Armonk, NY).  
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Results 
Wood 46 Expresses Lower Amounts of Cell Wall-Associated Protein A  
 
Flow cytometry using chicken anti-Protein A antibody was performed to determine 
the amount of cell wall-associated Protein A. The amount of binding was 
normalized against Seattle 1945 which showed maximum binding in this assay 
(assigned 100% binding). Wood 46 bound lower amounts of the antibody (about 
19%) relative to Seattle 1945. The Δsbi, Δspa and Δsbi-Δspa mutants bound 76%, 
27% and 9% of the antibody respectively. In contrast, Cowan 1 and the Newman 
WT isolate, both reported to be high producers of Protein A bound 69% and 83% 
respectively (Figure 2.1), indicating that Wood 46 may have lower amounts of cell 
wall-associated Protein A compared to the positive control strains used in this 
study.  
 
Secreted Protein A in Culture Supernatant of Wood 46 
 
S. aureus releases Protein A during the exponential growth phase [41, 42]. To 
confirm this in Wood 46, a Protein A-capture ELISA was used to measure the 
amount of Protein A secreted into culture supernatant. Both overnight (data not 
shown) and log phase culture supernatants were tested. Wood 46 secreted 12.42 
ng/ml of Protein A into the culture supernatant compared to Seattle 1945 which 
secreted the highest amount of Protein A (22.56ng/ml) during log phase (Figure 
2.2). These data indicate that Wood 46 produces and secretes Protein A, although 
the amount is lower, although not statistically significant, compared to Seattle 1945 
or wild-type Newman isolates.  
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Figure 2.1 Cell wall-associated Protein A in S. aureus.  
Protein A expressed on the surface of S. aureus strains Cowan1, Seattle 1945 
(25923), Wood 46, Newman WT and its corresponding deletion mutants, Δsbi, 
Δspa and Δsbi-Δspa, as measured by flow cytometry with chicken anti-Protein A 
antibody. The values represent the average from three independent experiments. 
(*P<0.05 and **P<0.02 were considered significant).  
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Figure 2.2  Production of extracellular Protein A in S. aureus.  
The amount of secreted Protein A was measured using an antigen-capture ELISA. 
Commercially available Protein A from S.aureus was used to generate the 
standard curve. The values represent the average from three independent 
experiments. (*P<0.05 was considered significant). 
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Gene Sequence Analysis of spa, srtA and Regulatory Region of srtA  
 
It was hypothesized that if the spa gene in Wood 46 harbors a mutation, it may 
lead to a truncated or non-functional protein. In order to test this hypothesis, the 
spa gene in Wood 46 and other S. aureus isolates was amplified using PCR and 
the products were sequenced and analyzed.  Results from the PCR and  DNA 
sequence analysis of the spa gene showed that Wood 46 not only possesses the 
full-length spa gene, but also the sequence of the spa gene is in complete 
agreement with those from Cowan 1, Seattle 1945 and wild-type Newman (data 
not shown). Therefore, mutation in the spa gene was ruled out as the possible 
cause for lower expression of Protein A in Wood 46.   
 
Sequence analysis of the srtA gene in Wood 46, however, showed that it has a 
12bp deletion at the 3’ end of the gene that results in a four amino acid difference 
in the protein compared to S. aureus Cowan 1, Seattle 1945 and wild-type 
Newman (Figure 2.3). Also, analysis of the upstream promoter and regulatory 
region showed that Wood 46 contains mutations in both the -10 and -35 regions 
(Figure 2.4). These mutations likely adversely affect RNA polymerase binding and 
transcription as mutations in the upstream promoter and regulatory regions have 
been associated with reduced gene expression [127-129].  
 
mRNA Levels of spa and srtA in Wood 46 
 
If the transcription of spa is adversely affected, it could lead to lower expression of 
Protein A on the bacterial surface. Reverse transcriptase qPCR was used to 
analyze the expression of spa in S. aureus isolates. The results showed that Wood 
46 transcribes spa mRNA although the levels were lower compared to  
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Figure 2.3  Amino acid composition of Sortase A.  
The amino acid sequence of Sortase A in Cowan 1, Seattle 1945, Newman and 
Wood 46 were aligned. Amino acids from position 155 to the end of the protein are 
shown. Wood 46 contains a 12bp deletion at the 3’ end of the srtA gene that leads 
to a corresponding loss of four amino acids at the C-terminus of the protein. 
 
 
 
 
Figure 2.4 Upstream promoter and regulatory region of srtA 
Consensus promoter and upstream regulatory sequence from Cowan 1, Seattle 
1945 and Newman was aligned with that of Wood 46. The boxes highlight regions 
with mutations. The transcription start site ATG is indicated as +1. 
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Cowan 1 (assigned as the calibrator for this experiment), Seattle 1945 (0.74 fold) 
and wild-type Newman isolate (Figure 2.5). As expected, the Δspa and Δsbi, Δspa 
mutants did not produce detectable spa mRNA. This suggests that inefficient spa 
transcription was not the reason for low surface expression of Protein A in Wood 
46. The spa expression level was normalized against 16S rRNA as the 
endogenous control and the results were expressed as fold change in mRNA 
levels using the ΔΔCT method. To ensure equal amplification efficiencies of the 
target and control genes, four 10-fold serial dilutions of the target RNA were tested. 
The efficiencies of both the target gene and the endogenous control were 
comparable.  
 
Conversely, the expression level of srtA mRNA in Wood 46 was below the limit of 
detection of the assay.  Cowan 1 was assigned as the calibrator strain for this 
experiment. The expression levels of Seattle 1945 and Newman WT were 0.26 
fold and 0.28 fold relative to Cowan 1, while that of the deletion mutants Δsbi, Δspa 
and Δsbi,Δspa were 0.14 fold, 1.03 fold and 0.51 fold respectively (Figure 2.6). 
Taken together, the results suggest the lack of Sortase A could be responsible for 
the deficient anchoring of Protein A in Wood 46.  
 
Wood 46 Expresses Lower Amounts of the LPXTG Motif-Harboring 
Fibrinogen-Binding Protein and Fibronectin-Binding Protein  
Sortase A is responsible for anchoring proteins with an LPXTG motif on to the 
peptidoglycan cell well [62, 64, 66, 124, 130]. If lack of this enzyme is indeed the 
reason for low surface density of Protein A in Wood 46, there should be a global 
decrease in the expression of all surface proteins that bear the LPXTG motif. In 
order to test this hypothesis, two well-studied proteins with LPXTG motifs were 
chosen. Fibrinogen-binding protein (Clf A and B) and fibronectin-binding protein  
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Figure 2.5 Expression levels of spa in S. aureus  
Quantitative real-time PCR was used to measure the amount of spa mRNA in log 
phase bacterial cells. Relative gene expression was calculated using the ΔΔCT 
method and expressed as fold change. 16S rRNA was used as the endogenous 
control. The values represent the average from three independent experiments. 
(*P<0.05 was considered significant). ND- not detected. 
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Figure 2.6 Expression levels of srtA in S. aureus.  
Quantitative real-time PCR was used to measure the amount of srtA mRNA in log 
phase bacterial cells. Relative gene expression was calculated using the ΔΔCT 
method and expressed as fold change. 16S rRNA was used as the endogenous 
control. The values represent the average from three independent experiments. 
(*P<0.05 and **P<0.02 were considered significant). ND- not detected. 
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(FnBP A and B) are anchored on the bacterial surface and known immune evasion 
factors in S. aureus. A binding assay was performed with FITC-labeled human 
fibrinogen to detect surface-expressed fibrinogen-binding protein, and HiLyte Fluor 
TM 488 conjugated bovine fibronectin to detect surface-expressed fibronectin-
binding protein. Flow cytometry results showed that Wood 46 bound only 0.49% 
of labeled fibrinogen on its surface compared to the Δspa isolate which bound the 
highest amount of fibrinogen in this study (Figure 2.7). Also, Wood 46 bound only 
11.4% of the labeled fibronectin relative to Cowan 1 (considered as 100%) and 
Seattle 1945 (31.2%) (Figure 2.8). The Newman isolate and its corresponding 
deletion mutants were not tested in the fibronectin-binding assay because they 
have truncations in both FnBP A and FnBP B [131]. These data suggest the lack 
of Sortase A in Wood 46 likely results in lower amounts of not just Protein A, but 
other proteins that bear the LPXTG motif.  
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Figure 2.7 Fibrinogen-binding assay.  
The amount of Sortase A-anchored, LPXTG-motif containing fibrinogen-binding 
protein was measured by flow cytometry using FITC-conjugated fibrinogen. The 
percentage binding was determined relative to highest value obtained for that 
experiment. The values represent the average from three independent 
experiments. (*P<0.05 and **P<0.02 were considered significant). 
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Figure 2.8 Fibronectin-binding assay.  
The amount of Sortase A-anchored, LPXTG-motif containing fibronectin-binding 
protein was measured by flow cytometry using HiLyte Fluor TM 488-conjugated 
fibronectin. The percentage binding was determined relative to highest value 
obtained for that experiment. The values represent the average from three 
independent experiments. (*P<0.05 and **P<0.02 were considered significant). 
(Since the Newman isolate has truncations in both FnBP-A and FnBP-B, it was not 
tested in the fibronectin binding assay).  
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Discussion 
 
S. aureus produces a number of virulence factors including secreted toxins, 
enzymes and cell wall-associated proteins that bind to and interact with host 
extracellular matrix [132]. In an in vitro environment, the production of virulence 
factors is growth-phase dependent [133]. The secreted proteins are produced  
during post-exponential (stationary) phase wheras the cell wall-associated 
proteins are predominantly produced during the logarithmic growth phase [134, 
135]. Many of the known virulence factors such as  Protein A, fibrinogen-binding 
proteins like clumping Factors A and B, fibronectin-binding proteins A and B are 
synthesized and anchored onto the peptidoglycan cell wall by the transpeptidase 
enzyme, Sortase A [66, 124, 130, 136].  
 
The S. aureus isolate Wood 46 has played an important role in studies designed 
to examine the biological function of Protein A and its role in pathogenesis and 
virulence. There have been contradictory reports on the production, display and 
secretion of Protein A [119, 137]. The results have either been ambiguous or 
lacked definitive experimental data. Wood 46 has been described as a spa-
negative and Protein A-deficient strain although there is evidence that Wood 46 
expresses low amounts of Protein A on its surface as evidenced by its ability to 
bind low amounts of IgG [119, 138]. It is also reported that Wood 46 secretes small 
amounts Protein A into the culture supernatant during exponential growth phase 
[118, 119]. Recently, several mutant strains have replaced Wood 46 as the 
preferred choice for negative control in both in vitro and in vivo studies. However, 
the mechanism for low expression of Protein A on the surface of Wood 46 had not 
been previously investigated.  
 
Cell wall-associated Protein A binds to IgG via its Fc region, thereby preventing it 
from opsonization and phagocytosis [36]. In this study, it was observed that Wood 
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46 had a lower density of Protein A on its surface and secreted less Protein A 
compared to the Cowan 1, Seattle 1945 or Newman isolates. It was observed that 
even the Δspa isolate bound some anti-Protein A antibody. This could be due to 
the ability of the antibody to react with other immunoglobulin-binding proteins on 
the surface of the bacterium. Secreted Protein A functions as a superantigen (SAg) 
[48]. It binds to VH3-clan B-cell receptors and limits their abilities to produce 
antibody. Also, marginal zone B-cells and B1-cells undergo apoptosis upon 
exposure to Protein A [44-48, 108]. There have been reports of secreted Protein 
A in Wood 46 activating human B-cells in a mechanism that is different from that 
seen in Cowan 1 [139]. Therefore, it is important to consider the toxic effects of 
secreted Protein A, if Wood 46 is used as a control in animal models to test vaccine 
efficacy.  
 
Conventional PCR and sequencing showed that Wood 46 possesses the spa gene 
with a complete open reading frame. The gene sequence is identical to that of 
Seattle 1945, Cowan 1 and Newman. qPCR for spa expression showed that Wood 
46 does transcribe spa mRNA but at lower amounts compared to that of Cowan 1, 
Seattle 1945 and Newman isolates.  Because this did not explain the low surface 
levels of Protein A, the transpeptidase enzyme Sortase A responsible for 
anchoring surface proteins on the peptidoglycan cell wall, was examined. 
Conventional PCR with srtA-specific primers showed that Wood 46 possesses the 
srtA gene with a complete open reading frame. However, it harbors a 12bp deletion 
at the 3’-end of the gene resulting in a corresponding loss of four amino acids at 
the N-terminus of the protein sequence. Further analysis of the upstream region of 
the srt A gene shows mutations in the -10 and -35 regions of the promoter and 
regulatory that would be expected to adversely affect binding of RNA polymerase 
and transcription. The functional effects of these mutations are yet to be evaluated 
and may be pursued at a later stage.  Promoter site mutations have been 
associated with impaired transcription and in turn affect protein expression [127-
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129, 140-143]. These mutations could affect the expression of srtA which in turn 
may be responsible for the low surface density of Protein A. If this is true, there 
should be a decrease in the expression of other surface proteins that harbor the 
LPXTG motif. This was confirmed by examining the surface expression of two 
known LPXTG proteins, fibrinogen-binding protein (Clf A and Clf B) and 
fibronectin-binding protein (FnBP A and FnBP B). Both these proteins in S. aureus 
are virulence factors similar to Protein A [62, 66, 108, 124, 125, 144]. Wood 46 
expressed very low amounts of both fibrinogen-binding protein and fibronectin-
binding protein on its surface suggesting that it may express lower amounts of all 
surface proteins that have an LPXTG motif.  The complete coding sequence of the 
Wood 46 srtA gene along with the upstream promoter and regulatory region has 
been deposited in GenBank (accession number: KY514391). The whole genome 
sequence of Wood 46 has been determined and deposited in GenBank (accession 
number: MTFQ00000000, version MTFQ00000000.1). This could provide a wealth 
of information about other immunoglobulin- binding proteins with or without an 
LPXTG motif. It will also help identify novel genes whose products may be involved 
in immune evasion. Sequence information about promoters and regulatory 
elements of virulence genes could help explain why some strains of  
S. aureus are innately less virulent compared to other highly virulent strains. 
In conclusion, the results from this study suggest that defective expression of srtA 
in Wood 46 accounts for the failure of Protein A anchoring to its surface with the 
majority of the Protein A being secreted. This may be accompanied by deficient 
anchoring of all LPXTG bearing surface proteins. The Wood 46 promoter at both 
the -10 and -35 regions contained mutations compared to the control strains used 
in this study. Promotors that vary from consensus sequences generally are 
associated with decreased gene expression [140, 141, 143]. Understanding the 
nature of surface protein expression and its role in virulence is crucial towards 
successful vaccine development against S. aureus 
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Here, we report the first complete genome sequence of the  
Staphylococcus aureus strain, Wood 46. Wood 46 has played an important 
role in understanding the virulence and pathogenesis of S. aureus 
infections. This report will assist efforts in vaccine development against 
MRSA infections.  
 
Staphylococcus aureus is a Gram-positive opportunistic pathogen that infects both 
humans and animals. It causes skin and soft tissue infections, and is also 
associated with septic arthritis, pneumonia, post-surgical and implant infections, 
osteomyelitis, septicemia and toxic shock syndrome [145, 146]. Methicillin-
resistant S. aureus (MRSA) is an important concern in hospitals (HA-MRSA), 
communities (CA-MRSA) and among livestock (LA-MRSA) [82, 146]. New vaccine 
discovery efforts rely on understanding the role of surface and/or secreted proteins 
in pathogenesis and infection [44, 147]. The S. aureus  
Wood 46 strain was reported to be Protein A-deficient and assumed to be spa 
negative [148]. It has also been shown to have reduced virulence in animal models 
of S. aureus infection [31, 107, 117-122, 149]. To date, the reason for reduced 
virulence and Protein A expression in the Wood 46 strain remains unknown. Whole 
genome sequence of this strain could provide insights into the genes, promoters 
and regulatory regions involved in pathogenesis and virulence. This in turn could 
help understand the role of specific virulence factors during infection and identify 
novel vaccine targets and/or develop novel strategies to combat MRSA infections.  
 
The S. aureus Wood 46 strain was sourced from the American Type Culture 
Collection (ATCC 10832). DNA was sequenced using Illumina MiSeq (Illumina, 
Inc., USA). De novo assemblies were individually produced and merged using 
Geneious (version 9.1.6) and CLC Genomics Workbench (version 9.0) 
(http://www.qiagenbioinformatics.com). Automated annotation was performed 
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using the NCBI Prokaryotic Genome Annotation Pipeline 
(http://ncbi.nlm.nih.gov/genome/annotation_prok).  
 
A total of 3,985,114 high-quality reads resulted in >180-fold overall coverage. The 
genome is 2,824,597 bp with a 32.8% GC content. The number of predicted coding 
sequences (CDS) and genes (RNAs) were 2806 and 73 respectively. The Wood 
46 genome shared 98%-99% identity with other published S. aureus genomes. 
The bacterium is susceptible to amoxicillin/clavulanic acid, cefoxitin, cephalothin, 
chloramphenicol, clindamycin, erythromycin, gentamicin, marbofloxacin, oxacillin, 
tetracycline and trimethroprim/sulfa, and resistant to ampicillin and cefpodoxime 
[150].  
 
Nucleotide sequence accession number: The Whole Genome Shotgun project 
of the S. aureus strain Wood 46 has been deposited at DDBJ/ENA/GenBank 
GenBank under the accession number MTFQ00000000. The version described in 
this paper is MTFQ00000000.1.  
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Abstract 
Staphylococcus pseudintermedius is a Gram-positive coccus and a common 
opportunistic pathogen in dogs. It causes skin and soft tissue infections, and is the 
most frequent cause of canine pyoderma. In the past few years, this organism has 
developed widespread resistance to methicillin. Many of the methicillin resistant S. 
pseudintermedius (MRSP) isolates are also multidrug resistant. The emergence of 
antimicrobial resistance has spurred the search for prophylactic methods for the 
control of these bacteria. Vaccine development, however, requires a deeper look 
into the surface properties of varying strains of S. pseudintermedius. S. 
pseudintermedius is known to produce a wide variety of virulence factors. Some 
of these are surface-associated while others are secreted.  
The purpose of this study was to analyze the whole secretome (secreted proteins) 
and surface-associated proteins in S. pseudintermedius by Mass Spectrometry 
(MS) in an effort to identify potential vaccine candidates. Three isolates 
representing the major clonal populations of S. pseudintermedius in the United 
States and Europe- 06-3228 (ST68), 08-1661 (ST71) and NA45 (ST84) - were 
selected for this study.  The specific objectives of this study were: (a) to analyze 
the entire bacterial secretome (b) to identify secreted immunoglobulin-binding (Ig-
binding) proteins and (c) to identify proteins accessible on the surface of the 
bacteria. 
The secretome, Ig-binding proteins and trypsin-treated proteins were compared 
among the three isolates using their respective genomes as reference databases. 
Orthologous proteins among the three isolates were identified and from this group, 
proteins common to all three isolates were further analyzed to determine if they 
were good vaccine candidates. 
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Introduction 
S. pseudintermedius is an opportunistic pathogen residing on the skin and mucosa 
of dogs and is frequently isolated from the nares, mouth, pharynx, forehead, groin 
and anus of healthy dogs and cats [7]. When the host immune system is 
suppressed or weakened, or if there is a breach in the external skin barrier, it can 
cause severe skin and soft tissue infections. It is the leading cause of clinical 
infections in dogs suffering from atopic dermatitis and is implicated in the 
pathogenesis of canine pyoderma [7, 8, 29]. Recently, the emergence of methicillin 
resistance and multidrug resistance in S. pseudintermedius has complicated 
treatment. This is due to limited treatment options and the often long duration and 
repeated treatments that are required to clear infection, sometimes extending over 
3-4 weeks along with a topical treatment [7, 8, 29, 81]. Such prolonged therapies 
may result in emergence of resistant bacteria. Once selected, this resistance may 
be horizontally transferred to other bacteria which may include human pathogens. 
Also, S. pseudintermedius has zoonotic potential and in rare cases has been 
reported to cause severe infections in humans, the most common route being dog 
bite wounds [7]. Therefore, there is an urgent need for effective methods to prevent 
and control S. pseudintermedius infections in dogs.  
 
The development of a successful vaccine against S. pseudintermedius requires a 
thorough understanding of the ecology and epidemiology of the bacteria, 
knowledge of bacterial and host factors involved in pathogenesis, and the nature 
of immune response. In the past, crude preparations based on S. aureus phage 
lysate or S. pseudintermedius autogenous bacterin had shown promise as 
adjunctive therapies to treat pyoderma [8, 15]. An efficacious vaccine administered 
either prophylactically or after the onset of an infection may be the most effective 
way of combating canine pyoderma.  
 
86 
 
Cell-wall associated (CWA) proteins produced by Gram-positive pathogens play a 
crucial rule in the pathogenesis of infection [15]. Surface-exposed and secreted 
proteins are more likely to interact with the host immune system. Several studies 
with S. aureus have indicated that CWA proteins represent promising targets for 
immunotherapeutic and vaccine design [151] . Little is known about the 
pathogenesis of S. pseudintermedius. However, S. pseudintermedius produces a 
number of virulence factors, including some which are functionally similar to those 
produced by S. aureus [22]. These include enzymes such as coagulase, 
proteases, thermonuclease, and toxins including hemolysins, exfoliative toxins and 
enterotoxins. S. pseudintermedius produces several CWA proteins that closely 
resemble those of S.aureus, including extracellular matrix (ECM) proteins 
fibrinogen-binding proteins, fibronectin-binding proteins, and cytokeratin [15, 22, 
29, 151]. Protein A encoded by the spa gene in S. aureus, one of the most potent 
immune evasion factors, also has a homologue in S. pseudintermedius designated 
as SpsQ (spa1) [15].  Along with Protein A, another immunoglobulin-binding 
protein, Sbi, in S. aureus, designated SpsK in S. pseudintermedius also functions 
as an immune evasion factor. Both these proteins are found abundantly on the 
bacterial surface but are not good vaccine candidates because of their toxicity and 
B-cell super-antigen activity [151].  
 
Vaccine studies with S. aureus suggest that multicomponent vaccine would be 
advantageous over killed or attenuated whole bacterial vaccine [152, 153]. Recent 
advancements in genome sequencing have made it possible to identify novel 
vaccine targets using reverse vaccinology. This technology has successfully been 
employed in S. aureus and vaccine development based on surface-exposed and 
secreted proteins have seen success in mouse models [154, 155]. The other 
important consideration during vaccine development is identification of targets 
conserved among a variety of strains. The identification of orthologous groups in 
prokaryotic genomes allows cross-referencing of genes from multiple 
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species/strains and facilitates genome annotation. Further, it makes possible the 
classification of protein families, bacterial evolution and identification of novel 
targets for antimicrobial drug development [156-159]. Mass spectrometry has also 
emerged as a powerful and efficient tool for analyzing proteins to identify 
biomarkers and vaccine targets [160].  
 
In the present study, mass spectrometry was used to identify the surface proteins 
and secreted proteins from three strains of S. pseudintermedius; 06-3228 (ST68), 
08-1661 (ST71) and NA45 (ST 84) which are representatives of the major clonal 
populations in the United States and Europe. Comparative analysis of the surface 
proteins and secreted proteins among these isolates could provide a wealth of 
information about strain similarities and differences, and identify novel proteins that 
could serve as vaccine targets.  
 
 
Materials and Methods 
Bacterial Strains and Growth Conditions  
 
S. pseudintermedius clinical isolates 06-3228 (ST68), 08-1661 (ST71) and NA 45 
(ST 84) were used for this study. The isolates were obtained from the Clinical 
Bacteriology Lab at the Veterinary Medical Center, University of Tennessee, 
Knoxville. Bacterial colonies from blood agar plates were inoculated into 5ml of 
sterile Trypticase Soy Broth (TSB) (BD Biosciences, San Jose, CA) and incubated 
overnight at 37°C with shaking at 225rpm (Excella E24 Incubator Shaker, New 
Brunswick Scientific). Fifty microliters of overnight culture were inoculated into 5ml 
of fresh, sterile TSB to initiate log-phase bacterial cultures. The bacteria were 
grown at 37°C with shaking at 225rpm until an optical density of OD 600 = 0.4-0.6 
was reached.  
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Preparation of Whole Secretome 
 
Log phase bacterial cultures were centrifuged at 10,000xg for 30 minutes at 4°C 
(Sorvall RC-5C Plus Superspeed Centrifuge). Without disturbing the bacterial 
pellet, the supernatant was collected and passed through a 0.45μm filter 
(Whatman, GE Healthcare Lifesciences, Pittsburgh, PA). The filtrate was 
concentrated using an Amicon®  Ultra-4 centrifugal filter (EMD Millipore Corp., 
Billerica, MA) and stored at -20°C until further analysis.  
 
Purification of Immunoglobulin-Binding Proteins from Bacterial Culture 
Supernatants 
 
Log phase bacterial cultures were centrifuged at 10,000xg for 30 minutes at 4°C. 
The supernatant was passed through an IgG-sepharose column (GE Healthcare 
Lifesciences, Pittsburgh, PA). Briefly, the column was equilibrated with five bed 
volumes of binding buffer containing 50 mM Tris, 2.7 mM potassium chloride and 
0.137 M NaCl pH 8.0. The bacterial supernatant was added to the column to allow 
attachment of IgG binding proteins. Unbound proteins were washed off with 15 
bed volumes of binding buffer. The bound proteins were eluted in 0.1-0.2 M 
Glycine/HCl pH 2.5-3.0. The pH of the elution fraction was adjusted to 7.0 using 
0.5M Tris and stored at -20°C until further analysis.  
 
Purification of Trypsin-Treated Surface Proteins 
 
Log phase bacterial cultures were centrifuged at 4,200xg for 3min and washed 
three times with PBS. The pellet was suspended in 1ml digestion buffer (0.6M 
sucrose buffered with 50mM Tris, pH 7.5).  Two hundred microgram of porcine 
trypsin (Sigma-Aldrich, St.Louis, MO) was added and the cells were digested for 1 
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hour at 37°C. Protease inhibitor cocktail set IV (Calbiochem, EMD Millipore Corp, 
Temecula, CA) was then added to the mixture at a final concentration of 0.1μg/ml. 
The supernatant containing tryptic peptides was stored at -20°C until further 
analysis.  
 
Biotin Labeling of Surface Proteins  
 
Log phase bacterial cells were harvested by centrifugation at 10,000xg for 1min 
and washed twice with ice-cold phosphate buffered saline (PBS) pH 8.0. One 
hundred microliters of 10mM EZ-Link Sulfo-NHS-LC-Biotin reagent (Thermo 
Scientific, Waltham, MA) per 1ml of cell suspension was added and incubated for 
30min at room temperature. The cells were washed three times with PBS and 
100mM glycine was added to quench and remove excess biotin. The biotin- 
labeled bacteria were stored in aliquots at -20°C until further use. The biotin-
labeled proteins were digested with trypsin as described previously and were 
stored at -20°C until further use.  
 
Purification of Biotin-Labeled Surface Proteins Using Monomeric Avidin  
 
Biotin-labeled surface proteins were purified using a monomeric avidin column 
(Pierce Monomeric Avidin Kit, Thermo Scientific, Waltham, MA) as per 
manufacturer’s protocol. Briefly, the monomeric avidin column was washed with 
8ml of PBS followed by the addition of 6ml of biotin blocking buffer to block any 
non-reversible biotin binding sites. The excess biotin was removed from the 
reversible binding sites by addition of 12ml of regeneration buffer. The biotin-
labeled, trypsin-cleaved proteins were loaded onto the column. Unbound proteins 
were washed off with PBS. The bound proteins were eluted using elution buffer in 
6 X 2ml fractions. The eluates were stored at -20°C until further use.  
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LC-MS/MS Analysis  
 
Samples interrogating S. pseudintermedius supernatant and surface-associated 
proteins were prepared for shotgun liquid crystallography-mass spectrometry (LC-
MS/MS) analysis. Trypticase soy broth (media alone) and bacterial culture 
supernatant passed through control Sepharose beads (without IgG) served as 
controls. Prior to protein denaturation with sodium dodecyl sulfate (SDS), samples 
were concentrated / solvent exchanged on molecular weight cut-off (MWCO) spin 
filters (Vivaspin, GE Healthcare Lifesciences, Pittsburgh, PA) that retain 
proteins/polypeptides > 5kDa in size (~ 50 amino acids or larger). Retained 
proteins were then re-suspended in 4% SDS, 100mM Tris-HCl, 5mM dithiothreitol 
(DTT), transferred to microcentrifuge tube, and incubated at 95°C for 5min. 
Iodoacetamide was then added to a final concentration of 15mM and samples 
incubated for 20 min in the dark at room temperature. Denatured and reduced 
proteins were then digested to peptides with 2μg of proteomics-grade porcine 
trypsin (Sigma-Aldrich, St.Louis, MO) for 4 hours. Following digestion, peptide 
samples were adjusted with 200mM NaCl-0.1% formic acid and passed through a 
10kDa MWCO Vivaspin2 spin filter to collect appropriately sized tryptic peptides 
for LC-MS/MS analysis. 
With the aid of a pressure cell, peptides were loaded onto a biphasic MudPIT back 
column containing both strong-cation exchange and reversed-phase (RP) resins-
5u Luna or 5u Kinetex, respectively (Phenomenex, Torrance, CA) and separated 
as previously detailed [161]. Briefly, loaded samples were washed offline then 
placed in line with an in-house pulled nanospray emitter packed with 15cm of RP 
resin. Peptides were then separated and analyzed with either a 2-step MudPIT LC-
MS/MS protocol (salt cuts of 50mM and 50mM ammonium acetate) over a 4-hr 
period (supernatant samples) or a 1-step protocol (500mM ammonium acetate) 
over a 2-hr period (surface proteins and pulldown samples). All samples were 
measured with a hybrid LTQ XL-Orbitrap (Thermo Scientific, Waltham, MA) mass 
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spectrometer (MS) as follows: data-dependent acquisition, 1 full scan followed by 
10 MS/MS scans. Orbitrap mass analyzer was set to 15K resolution, LTQ isolation 
window = 2.2 m/z, monoisotopic precursor selection, dynamic exclusion window, 
duration, and max = 3 m/z, 60s (30s for supernatant samples), and 500 
respectively. The immunogenicity of peptides was predicted using the POPI v.2.0 
web server.  
 
Results 
LC MS/MS Data Analysis  
 
LC-MS/MS spectra were searched against sample-specific proteome databases 
[103] concatenated with common protein contaminants using MyriMatch v.2.2 
[162]. Peptide spectrum matches (PSM) were filtered and assembled to proteins 
using IDPicker v.3.0 [163] with false-discovery rates, as assessed by evaluating 
MS/MS spectra that matched to reversed decoy sequences, controlled at < 1% at 
the peptide-level. Protein calls required two distinct peptides at a minimum. 
Peptide intensities were assessed by chromatographic area-under-the-curve 
(AUC) using IDPicker’s embedded spectra/label-free quantification option and 
protein abundances derived via summation of constituent peptides intensities. To 
qualitatively compare the proteins identified across each strain of  
S. pseudintermedius, OrthoMCL (OrthoMCL Database, Version 5.0) [164-166] 
was employed to identify orthologous protein sequences. Identified protein data 
for each specific S. pseudintermedius sequence type were then re-cast into their 
orthologous groups and compared across all sample types to identify proteins 
common to all three pathogenic strains – with special emphasis on those that are 
surface-associated and/or secreted. To help winnow down the list of potential 
secreted and surface-bound antigen targets, PSORTb v.3.0 [167] was used to 
assign subcellular location to each identified protein.  
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Identification of Surface Proteins, IgG-Binding Proteins and Extracellular 
(Secreted) Proteins by Mass Spectrometry 
 
Using the analysis method described above, a total of 580 proteins were identified 
in the isolate 06-3228 (ST68), 596 in 08-1661 (ST71) and 542 in NA45 (ST84). 
The number of proteins in each fraction is listed in Table 4.1 and the percentage 
of proteins in each fraction for individual isolates, 06-3228 (Figure 4.1), 08-1661 
(Figure 4.2) and NA45 (Figure 4.3) is depicted.  
 
Orthologous Proteins in 06-3228, 08-1661 and NA45 
 
In order to narrow down the spectrum of proteins for analysis across all three 
sequence types, orthologous protein prediction was performed using the web-
based tool OrthoMCL. A total of 364 predicted orthologous proteins were identified 
across all three sequence types. Excluding proteins that were classified as 
cytoplasmic in origin, there were 72 proteins predicted to be either secreted 
(17/72), cell wall-associated (10/72) or of unknown cellular location (45/72) across 
all three sequence types. The percentage of orthologous proteins based on their 
location is shown in Figure 4.4. Isolate 06-3228 had at least 10 proteins that were 
predicted to be cell wall-associated and 16 extracellular proteins. Isolate 08-1661 
had 10 proteins predicted to be cell wall-associated and 17 extracellular proteins 
while isolate NA45 had 9 predicted cell wall-associated proteins and 14 
extracellular proteins. From this list, eight proteins common to all three isolates 
were identified that could potentially function as antigens. This includes: predicted 
cell wall-anchored protein SasF (LPXAG motif), beta-hemolysin, gamma-
hemolysin component B, secretory antigen precursor, SsaA, fibronectin-binding 
protein FnbB, oligopeptide ABC transporter, virulence-associated cell wall-
anchored protein SasH (LPXTG motif) and exotoxin 15. 
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Table 4.1 Total number of predicted proteins in each of the fractions 
analyzed by mass spectrometry for isolates 06-3228, 08-1661 and NA45 
Isolate Sequence 
Type 
Secreted 
Proteins 
IgG-
Binding 
Proteins 
Surface 
Proteins 
Biotinylated 
Surface 
Proteins 
Total 
06- 
3228 
ST68 202 38 234 106 580 
08- 
1661 
ST71 237 26 274 59 596 
NA45 ST84 162 66 260 54 542 
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Figure 4.1 Percentage of proteins predicted in each fraction for isolate 06-
3228 
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Figure 4.2 Percentage of proteins predicted in each fraction for isolate 08-
1661 
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Figure 4.3 Percentage of proteins predicted in each fraction for isolate NA45 
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Figure 4.4  Percentage of predicted orthologous proteins across all three 
isolates.  
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Additionally, three proteins, putative peptidoglycan bound protein (LPXTG) motif 
Lmo1799 homolog, immunodominant staphylococcal antigen A precursor and zinc 
metalloproteinase precursor/aureolysin) that were identified only in isolates 08-
3228 and 08-1661 could also be potential antigenic targets (Table 4.2).  
  
Identification of Peptides with High Immunogenic Potential  
 
Peptide sequences from the eight proteins were tested for their immunogenicity 
using the online immunogenicity prediction tool POPI v.2.0. Sequences 
corresponding to SasF, SsaA, SasH, FnBP and exotoxin 15 are predicted to be 
good vaccine candidates. Taken together, the results suggest that Mass 
Spectrometry, along with orthologous protein prediction could be a good strategy 
to scan for potential vaccine targets in S. pseudintermedius.  
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Table 4.2 List of orthologous proteins identified across all three isolates with 
their predicted cellular location 
  Predicted Protein  Cellular 
Location 
All 3 
sequence 
types  
Predicted cell-wall-anchored protein 
SasF (LPXAG motif) 
Cell wall 
Virulence-associated cell-wall-anchored 
protein SasH (LPXTG motif) 
Cell wall 
Fibronectin binding protein FnbB Cell wall 
Oligopeptide ABC transporter  Cell wall 
Beta-hemolysin Extracellular 
Gamma-hemolysin component B Extracellular 
Secretory antigen precursor SsaA Extracellular 
Exotoxin 15 Extracellular 
ST68 and 
ST 71 
Putative peptidoglycan bound protein 
(LPXTG motif) Lmo1799 homolog 
Cell wall 
Immunodominant staphylococcal antigen 
A precursor 
Extracellular  
Zinc metalloproteinase 
precursor/aureolysin 
Extracellular  
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Discussion 
The increasing prevalence of methicillin resistance and multidrug resistance 
among staphylococci has given rise to ‘superbugs’ that can no longer be treated 
with conventional antibiotics. This is especially difficult in veterinary medicine 
where the number of antibiotic choices available to treat S. pseudintermedius 
infections is limited. Therefore, it has become important to seek alternative 
treatment strategies, such as preventative or therapeutic vaccines. In the past, 
attempts to generate S. aureus vaccines based on whole-cell determinants and/or 
virulence factors have failed to induce protective immunity in humans, although 
they have demonstrated promising results in animal models [44, 84-86, 168, 169]. 
A multivalent vaccine is considered the best strategy for vaccine development 
against S. aureus [112, 153, 169-171]. A successful vaccine against 
staphylococcal infections should be able to elicit three major immune responses 
(a) humoral immune response i.e., antibodies to directly inhibit bacterial viability 
and/or toxicity (b) antibodies to mediate opsonophagocytosis and  (c) a cell-
mediated T-helper 1 (Th1)/Th17 response. Identifying novel vaccine candidates 
requires extensive analysis of the proteome of S. pseudintermedius. Surface 
proteins, particularly cell wall-associated proteins and secreted proteins are most 
likely to come in contact with the host, and therefore contribute to the virulence 
and pathogenesis. Keeping these factors in mind, the present study analyzed the 
secretome and surface proteins in three distinct isolates, 06-3228 (ST68), 08-1661 
(ST71) and NA45 (ST84) of S. pseudintermedius by mass spectrometry to identify 
novel vaccine targets. Bannoehr et al., had employed a combination of genomic 
and proteomic approach to analyze the surface proteins in the S. 
pseudintermedius strain ED99 [15]. They were successful in identifying 60 surface 
proteins, including those involved in adhesion.  
 
In the present study, the secretome and surface-associated proteins in three 
different S. pseudintermedius isolates was analyzed by mass spectrometry. LC-
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MS/MS analysis of surface-associated/exposed supernatant and proteins 
expressed by S. pseudintermedius sequence types identified a total of 364 
orthologous proteins across all sample types. As revealed by PSORT, a large 
majority of these proteins were cytoplasmic in origin and were largely identified in 
the supernatant proteomes of each subspecies – a finding that often results from 
natural and unavoidable cell lysis over the course of organism growth. These 
cytoplasmic “contaminants” are known to be abundant and are generally involved 
in central carbon metabolism and organism biogenesis. As these proteins are 
irrelevant to this current study, only those proteins classified a non-cytoplasmic in 
origin, i.e. those that are cell wall-associated, membrane-associated, extracellular 
or unknown/unclassified were the focus of this study. When confining our view to 
only these non-cytoplasmic proteins, only 72 proteins remained. As the goal of this 
study was to identify secreted or surface-bound protein antigen targets for vaccine 
development against pathogenic (MRSP) strains of S. pseudintermedius, these 72 
proteins were analyzed in the context of the various enrichment strategies 
discussed above with particular attention paid to those that were surface-exposed 
and/or secreted, found across all three sequence-types. Eight candidate proteins 
were identified that could serve as viable antigen targets. These peptides are as 
yet to be tested for their immunogenic potential. Proteins that were annotated as 
hypothetical or those predicted with an unknown cellular location were excluded 
from this study. Further characterization of these hypothetical proteins is required 
to determine if any of them are good vaccine candidates.  
 
Using a combination of mass spectrometry and orthologous protein prediction, it 
was possible to identify novel antigenic targets in three S. pseudintermedius 
isolates representing three distinct sequence types. Using the same strategy, it is 
possible to determine if all clinically relevant S. pseudintermedius strains express 
these proteins in high frequency which will further aid in the development of a 
multicomponent vaccine against S. pseudintermedius infections.  
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CHAPTER 5.  
Identification of Staphylococcus pseudintermedius Sortase A 
Inhibitors 
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Abstract 
Conventional antibiotic-based therapies against S. pseudintermedius infections 
have failed in recent years, due to the increased prevalence of methicillin 
resistance and multidrug resistance.  Therefore, alternate strategies for treatment 
have to be explored. Anti-infective therapy based on sortase inhibition holds 
potential to address this shortcoming. Sortase A (SrtA) is a transpeptidase, 
commonly produced by Gram-positive bacteria, that recognizes proteins with a C-
terminal LPXTG motif and anchors them on the peptidoglycan cell wall. SrtA 
substrates include numerous virulence factors and proteins that may overcome the 
host immune response including Protein A, fibrinogen binging proteins and 
fibronectin binding proteins.   
 
In the present study, a srtA gene from S. pseudintermedius was synthesized, 
inserted into an expression vector and expressed in E.coli. A commercially 
available synthetic substrate for SrtA, Abz-LPETG-K(Dnp)-NH2, was used to 
assess the function of the recombinant enzyme. Using molecular dynamic 
simulations, a 3-D homology model of SrtA was created to screen a library of 
compounds from drug databases for potential inhibitors. From the predicted top 
twenty most active inhibitors, ten were selected and tested for their ability to inhibit 
sortase in-vitro. Four out of ten compounds showed ~50% inhibition of 
recombinant SrtA activity. These compounds were further evaluated for their ability 
to inhibit SrtA in bacterial culture. The results indicate the possibility of SrtA 
inhibition as a potential therapeutic strategy in the treatment of staphylococcal 
infection in both humans and animals.  
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Introduction 
S. pseudintermedius is a skin and mucous membrane commensal of dogs and is 
the organism most frequently associated with atopic dermatitis and wound 
infections in dogs. It is also implicated in the pathogenesis of canine pyoderma [7, 
8]. In the past, antimicrobial agents have been used to successfully control  
S. pseudintermedius infections. However, in recent years, there has been an 
increased prevalence of methicillin resistance and multidrug resistance among  
S. pseudintermedius isolates [5, 7, 80, 95, 98, 172]. This has made treatment of 
infection difficult due to the limited number of antimicrobial agents used in 
veterinary medicine [173]. Therefore, there is an urgent need for the development 
of non-antibiotic based treatment strategies to combat  
S. pseudintermedius infections.  
 
Surface proteins in S. aureus harboring a C-terminal sorting signal with an LPXTG 
motif are covalently attached onto the peptidoglycan cell wall by the enzyme SrtA 
which is encoded by the srtA gene [62, 69]. This 618bp gene encodes a protein of 
206 amino acids with a molecular weight of 23.59kDa. The enzyme is a cysteine 
transpeptidase that recognizes the conserved LPXTG motif in surface proteins and 
specifically cleaves between the threonine (T) and glycine (G) residues. The active 
site cysteine of SrtA forms an acyl enzyme intermediate that is relieved by the 
nucleophilic attack of the amino group of the pentaglycine cross bridge in 
peptidoglycan synthesis precursors. The N-terminus of the enzyme is located in 
the cytoplasm while the C-terminal enzymatic region is located across the plasma 
membrane (type II membrane topology) [62]. His120, Cys184 and Arg197 form the 
catalytic triad of the enzyme and are found to be conserved among sortases in S. 
aureus [62, 68]. Surface proteins attached to peptidoglycan precursors are then 
incorporated into the bacterial cell wall and displayed on the surface [58, 62, 63, 
65, 66, 68, 70, 124]. There are at least 17-21 surface proteins in S. aureus that 
harbor the LPXTG motif. Most of these proteins are involved in virulence and 
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pathogenesis [62, 124]. SrtA is essential for the functional assembly of all surface 
proteins harboring an LPXTG motif, and therefore plays a crucial role in the 
pathogenesis of S. aureus infections.  
S. aureus mutants that do not have a functional srtA gene fail to assemble surface 
proteins on to the peptidoglycan cell wall. Also, they are unable to form abscess 
lesions in organ tissues or cause lethal bacteremia in mice models of S. aureus 
infections [57]. Therefore, inhibition of SrtA could result in defective display of all 
the proteins harboring the LPXTG motif and render the organism less virulent.  
SrtA inhibitors, therefore, may be useful as anti-infective agents particularly in 
cases where there is methicillin resistance and multidrug resistance, and disrupt 
the pathogenesis of bacterial infections without affecting microbial viability [57, 70, 
174]. The earliest described inhibitors of SrtA include methane-thiosulfonates such 
as MTSET,   and p-hydroxymercuribenzoic acid. All these compounds interact with 
Cys184 and render the enzyme inactive [62]. Other natural or chemical compounds 
have also been examined for their abilities to inhibit SrtA [62, 175]. Although 
identification of inhibitors for SrtA has been ongoing for several years, it has gained 
momentum in the last decade due to the advancements in genomics and 
proteomics [56].  
 
SrtA in S. pseudintermedius has not been previously examined. In this study, the 
srtA gene in S. pseudintermedius was identified, cloned and expressed in E. coli. 
Molecular dynamic (MD) simulation using the bioinformatics tool MOE 
(Mathematical Operating Environment) was used to generate a 3-D homology 
model of S. pseudintermedius SrtA using the existing 3-D model of S. aureus SrtA. 
After identifying the active site of S. pseudintermedius SrtA, scaffold hopping and 
molecular docking were combined to virtually screen the drug databases NCI 
(National Cancer Institute) and Zinc to identify potential inhibitors of S. 
pseudintermedius SrtA. Ten potential inhibitors were identified and purchased 
from NCI. Of these ten compounds, four inhibited recombinant SrtA in an in vitro 
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functional assay using a synthetic SrtA substrate Abz/DNP (Abz-LPETG-K(Dnp)-
NH2 by at least 50%. These inhibitors were further tested for their ability to inhibit 
SrtA in actively growing bacterial cultures. One of the compounds, 1847, showed 
at least 50% inhibition of SrtA in actively growing bacterial cultures, suggesting the 
possibility of SrtA inhibition as an anti-infective therapy against S. 
pseudintermedius infection.  
 
Materials and Methods 
Identification of the srtA gene in S. pseudintermedius 
 
Whole genome sequences of several S. pseudintermedius isolates representing 
the major clonal populations in the United States and Europe were available for 
analysis [103]. The srtA gene from these isolates was identified by a combination 
of BLAST (using the S. aureus srtA gene as reference) and conserved domain 
search. Multiple sequence alignment (MSA) of the srtA gene from various isolates 
was performed to generate a consensus sequence. This sequence was used to 
design primers for conventional and quantitative real-time PCR (qPCR) assays.  
 
Bacterial Strains and Growth Conditions  
 
S. pseudintermedius clinical isolates (Table 5.1) were selected based on their 
multilocus sequence types [6]. Bacteria from blood agar plates were used to 
inoculate trypticase soy broth (TSB, Becton Dickinson, Franklin Lakes, NJ) and 
were grown at 37°C overnight with shaking at 225rpm. After an overnight 
incubation, 50µl of broth culture were inoculated into 5ml of sterile TSB and 
incubated for 3hr at 37°C with shaking to obtain log phase cultures (OD600 = 0.4-
0.6) which were used for all experiments. 
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Table 5.1 Bacterial isolates used in this study along with their sequence type 
and methicillin resistance profile 
Strain Sequence Type Methicillin 
Resistance 
06 3228 ST68 R 
08 1294 ST68 R 
08 521a ST68 R 
E140 ST71 R 
08 1661 ST71 R 
NA16 ST71 R 
NA12 ST64 R 
NA45 ST118 R 
KM 241 ST73 S 
ED99 ST25 S 
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DNA and RNA Extraction for Conventional and Real-Time PCR 
 
Bacterial DNA was extracted from overnight cultures using a commercial kit 
(MoBio Ultra Clean DNA Isolation Kit, MoBio, Carlsbad, CA) according to the 
manufacturer’s protocol. PCR for srtA gene was performed using the following 
primers. SP sortase fwd: 5’-ACTGCGATAAACAGTAACCACTA-3’ and  
SP sortase rev: 5’-CGCTCTCCAACACCATTAAC-3’. The following cycling 
conditions were performed: initial denaturation at 95°C for 90s followed by 30 
cycles of annealing at 55°C for 30s and extension at 72°C for 1min, and a final 
extension at 72°C for 5min. PCR products were sequenced (The University of 
Tennessee, Genomics Core Facility), aligned, and compared using Geneious 
7.1.7.0 (Biomatters, Auckland, New Zealand). 
Total RNA was extracted from log phase bacterial cultures using a commercial kit 
(MoBio Ultra Clean RNA Isolation kit, MoBio, Carlsbad, CA) according to the 
manufacturer’s protocol.  Quantitative Real-Time PCR (qPCR) for srtA was 
performed using the TaqMan RNA-to-CT 1-Step kit on an ABI StepOne PCR 
System (Applied Biosystems, Foster City, CA) using the following primer-probe 
set. Probe: 5’-/56-FAM/TCGCTATTG/ZEN/CGGGACATACGAATT/3IABkFQ/-3’, 
Primer 1: 5’-GGATGAATCACTCAAAGACC-3’ and Primer 2:  
5’-CGCTTTGCTTAACTCTGTAA-3’. The following cycling conditions were 
performed: 48°C for 30min, 95°C for 10min, 95°C for 15s, 60°C for 1min (40 
cycles). qPCR data were analyzed by the ΔΔCT method and normalized against 
16S rRNA as the endogenous control as previously described [104]. 
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SrtA Expression and Purification 
 
A synthetic srtA gene for S. pseudintermedius Sortase A with a 6X-His tag at the 
3’ end was designed, codon optimized for expression in E. coli, synthesized and 
inserted into the expression vector pET11a (GenScript Inc., Piscataway, NJ). 
Briefly, 5ng of the pET11a plasmid harboring the srtA gene was transformed into 
competent E. coli BL21 (DE3) (New England BioLabs, Ipswich, MA) by heat shock 
for exactly 10s at 42°C. The mixture was immediately placed on ice for 5min and 
950μl of SOC outgrowth medium (New England BioLabs, Ipswich, MA) was added, 
and allowed to incubate at 37°C with shaking for 1hr. After 1hr, 25μl and 75μl of 
the transformed E.coli was plated on pre-warmed LB-amp (Luria-Bertani with 
100μg/ml ampicillin) plates and incubated overnight at 37°C.  
 
Recombinant colonies were picked and inoculated into LB-amp broth and grown 
overnight at 37°C on a shaker incubator at 225rpm. One milliliter of overnight 
culture was inoculated into 100ml of LB-amp broth and allowed to grow till an 
OD600=0.4-0.6 was reached. Protein expression was induced by adding 1mM 
isopropyl 1-thio-β-d-galactopyranoside (IPTG, Sigma-Aldrich, St.Louis, MO) at 
30°C for ~4hr. Cells were harvested by centrifugation at 10,000xg for 30min. The 
bacterial pellet was resuspended in 5ml of Bug Buster solution (Millipore-Novagen, 
Temecula, CA) along with protease inhibitor cocktail IV (Millipore-Calbiochem, San 
Diego, CA) and incubated at room temperature for 20-30min with shaking to 
facilitate cell lysis. The lysate was clarified by centrifugation at 10,000g for 30min 
at 4°C and recombinant protein was enriched on an Ni-TED column (PrepEase 
His-tagged protein purification kit, Affymetrix Inc, Santa Clara, CA) and His-tagged 
SrtA was eluted from the column as per the manufacturer’s protocol. The purity of 
the protein was determined by SDS-PAGE and western blot using monoclonal anti-
His antibody-HRP conjugate (Thermo Scientific, Rockford, IL).  
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Homology Modeling of Sortase A and Virtual Screening for Sortase A 
Inhibitors 
 
The predicted S. pseudintermedius SrtA protein sequence was compared to that 
of S. aureus SrtA using the BLAST algorithm and conserved domain search 
feature in NCBI. The proteins share 57% identity at the amino acid level. His114, 
Cys177 and Arg190 are predicted to be a part of the catalytic triad site involved in 
attacking the LPXTG motif in S. pseudintermedius [68]. Molecular Dynamic (MD) 
simulation was performed using the bioinformatics tool MOE (Molecular Operating 
Environment) to generate a 3-D homology model of  
S. pseudintermedius SrtA. Enzyme coordinates were mapped and the catalytic 
and active sites including the amino acids involved in substrate binding were 
predicted. The enzyme structure at one of many coordinates was fixed and this 
structure was initially used to screen the drug database NCI (National Cancer 
Institute). Compounds predicted to bind to the active site were identified. Initially, 
from the 200 highest ranked compounds, twenty were selected. Of the 20, the 10 
most active compounds were purchased and tested in the in vitro assay.  
For the second iteration, compounds that showed >50% inhibition in the in vitro 
assay were selected. The common structural features of these compounds were 
identified in an attempt to find inhibitors with higher binding affinities for SrtA. With 
the refined search parameters, the drug database Zinc was screened. Ten 
compounds were evaluated for their inhibitory potential in the in vitro assay.  
 
Enzymatic Activity of Sortase A 
 
The functional activity of recombinant SrtA was performed in 96-well black 
microtiter plates with clear bottom (Corning, Fisher Scientific, Hampton, NH) in a 
final reaction volume of 200μl. Fluorescent- quenched bacterial sortase substrate 
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III, Abz/DNP (Abz-LPETG-K(Dnp)-NH2 (GenScript Inc., Piscataway, NJ) dissolved 
in isopropanol was used for Km determination. Varying concentrations of the 
substrate (2.5μM - 200μM) were incubated at 25°C with 1μM of SrtA diluted in 
assay buffer (50mM Tris-HCl, 150mM NaCl, 5mM CaCl2, and 0.1% Triton X-100, 
pH 7.5). The increase in fluorescence was measured in a kinetic assay for 20min 
at 2min intervals using a Synergy HTX multimode reader (BioTek, Winooski, VT) 
at wavelengths 320 excitation/420 emission. The initial velocity V0 was determined 
from the linear portion of the curve and the Km was determined using the Michaelis-
Menten equation where V=Vmax[S]/([S]+Km).  
 
In vitro Sortase Inhibition  
 
The assay developed by Kruger et al. was modified and used to determine the 
activity of recombinant SrtA [176]. Bacterial sortase substrate III, Abz/DNP (Abz-
LPETG-K(Dnp)-NH2 (GenScript Inc., Piscataway, NJ) was dissolved in 
isopropanol to a final concentration of 1mM. Recombinant SrtA was pre-incubated 
with varying amounts of the inhibitor at 37°C for 30min. One hundred micromolar 
of the FRET substrate was added to the wells of a 96-well black microtiter plate 
with clear bottom (Corning, Fisher Scientific, Hampton, NH). One hundred 
microliters of the SrtA-inhibitor mixture was added and the incubated at room 
temperature for 20min. The amount of fluorescence was measured using a 
Synergy HTX multimode reader (BioTek, Winooski, VT) at wavelengths 320 
excitation/420 emission. A titration experiment was performed to determine the 
optimal amount of the enzyme and inhibitor to be used for each assay.  
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Sortase Inhibition in Bacterial Cells  
Bacterial colonies from blood agar plates were inoculated into 5ml of TSB and 
grown overnight at 37°C with shaking. Fifty microliters of overnight culture were 
inoculated into 5ml of fresh TSB along with 100μg/ml of the inhibitor and allowed 
to grow until log phase (OD600 = 0.4-0.6) was reached. One milliliter of culture was 
aliquoted into a micro centrifuge tube and centrifuged at 10,000xg for 1min. The 
pellet was washed twice and suspended in 1ml of PBS. One hundred microliters 
of chicken anti-protein A antibody conjugated to FITC (Gallus Immunotech, Cary, 
NC) was added and incubated at room temperature for 30min in the dark. Unbound 
antibody was washed off and the pellet was suspended in a final volume of 1ml 
PBS. The amount of bound fluorescent antibody was measured by flow cytometry 
using an attune acoustic focusing cytometer (Applied Biosystems, Foster City, CA) 
at excitation/emission wavelengths of 488/519 nm. Data were acquired in linear 
mode for forward and side scatter and logarithmic mode for fluorescence. For each 
sample, 10,000 events were measured. Also, for each isolate, cells incubated with 
PBS instead of the inhibitor served as the negative control to distinguish between 
inhibition and non-inhibition.  
 
Statistical Analysis 
A one-way ANOVA and multiple comparisons using Tukey’s honest significant 
difference were performed to test if there was a significant difference in the 
expression of srtA among bacterial isolates, and also to determine if there was a 
significant difference in the inhibition assay. Each experiment was repeated at 
least three times and a p-value of <0.05 was considered significant. All analyses 
were conducted using the GraphPad Prism software (Version 7, GraphPad 
Software Inc, La Jolla, CA). 
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Results  
S. pseudintermedius contains an srtA Gene Homologous to srtA Found in S. 
aureus 
 
Whole genome sequence analysis of several S. pseudintermedius isolates 
revealed that S. pseudintermedius contained a srtA gene homologous to the one 
found in S.aureus. The srtA gene in S.pseudintermedius is 597bp in length and 
codes for a 198 amino acid protein (Figure 5.1) with a predicted molecular weight 
of 22.36kDa.  
Conventional PCR with S. pseudintermedius srtA-specific primers showed that 
isolates representing the major clonal populations in the United States and Europe 
(Table 5.1) contained the srtA gene. qPCR data suggested that the fold change in 
expression for isolates 08-1294 and 08-521a were 0.76 fold and 0.4 fold 
respectively. Fold change in expression for isolates form sequence type ST71 
were 0.75 fold (08-1661), 4.12 fold (E140) and 3.47 fold (NA16). Isolate 06- 3228 
was assigned as the calibrator for this experiment. The amount of srtA mRNA was 
normalized against 16S rRNA as the endogenous control (Figure 5.2). These 
results indicate that the srtA mRNA in S. pseudintermedius could be detected and 
quantified.  
 
Recombinant S. pseudintermedius SrtA 
 
The full-length recombinant, his-tagged SrtA protein was purified from E. coli BL21 
(DE3). The molecular weight of the recombinant protein was ~23kDa and was 
confirmed by SDS-PAGE and western blot (Figure 5.3). The concentration of the 
protein was estimated by Bradford method and found to be 0.5-1mg/ml per 100ml 
batch of E. coli culture. 
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ATGCAAAAATTAACACGTGGGTTGGTTCCACTTATTGGTATTGCATTGATTTTAGCAGG
CGTATATTTAATCTTTAAGCCGAAAATTGATGCATATTTGACCAATAAAGAAAATGAAC
AAAAAATTGAAGTATATGAAGAAAGTCAACAAAATGCACCATCAAAAGTGCCTGAAATT
CCGAAAGACCCGTCGAAAGTCGTTGGTGTATTAGAAGTGCCGTCAGTCGGTATAAAAGA
AGCTGTGTATCCTGGTCCTGCGACACCTGAACAATTGGAGCGCGGTGTCAGTTTGGCGG
AAAAGGATGAATCACTCAAAGACCAAAATATCGCTATTGCGGGACATACGAATTATAGT
TTGAACTATCAATTTACAGAGTTACACAAAGCGAAAAAGGGTGCAGAAGTAATTTTTAA
ACTGGGTAAAGAAACGCGCAAATATCAAATTACGTCGATTAAAGATGTCGATCCGTATC
AAGTTGAAGTGTTGGAAGAGATGAAGAAAGATAAAGACCAACTGACACTCATTACTTGT
GATGATTACGATGAGAAAACAGGTCAGTGGCTGACACGCAAAATTTATGTAGCTGAACG
TGTGTAG 
 
MQKLTRGLVPLIGIALILAGVYLIFKPKIDAYLTNKENEQKIEVYEESQQNAPSKVPEI
PKDPSKVVGVLEVPSVGIKEAVYPGPATPEQLERGVSLAEKDESLKDQNIAIAGHTNYS
LNYQFTELHKAKKGAEVIFKLGKETRKYQITSIKDVDPYQVEVLEEMKKDKDQLTLITC
DDYDEKTGQWLTRKIYVAERV 
 
Figure 5.1 Consensus gene sequence and predicted amino acid sequence of 
SrtA in S. pseudintermedius.  
The srtA gene in S. pseudintermedius is 597bp in length and codes for a protein 
with 198 amino acids.  Based on amino acid conservation with S. aureus SrtA, the 
amino acids predicted to be critical for enzymatic activity are highlighted. 
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Figure 5.2  Expression levels of srtA in S. pseudintermedius.  
Quantitative real-time PCR was used to measure the amount of srtA mRNA in log 
phase bacterial cells. Relative gene expression was calculated using the ΔΔCT 
method and expressed as fold change. 16S rRNA was used as the endogenous 
control. The values represent the average from three independent experiments. 
(*P<0.05 was considered significant).  
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Figure 5.3  SDS-PAGE and Western Blot analysis of recombinant SrtA.  
Western blot analysis of recombinant SrtA in one of the elution fractions using anti-
His antibody. The molecular weight of the protein corresponded to ~23kDa. E1, E2 
and E3 are three separate elution fractions.   
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3-D homology model of SrtA and Identifying Sortase Inhibitors 
The S. pseudintermedius SrtA protein sequence was compared to that of S.aureus 
SrtA. Molecular Dynamic (MD) simulation was performed using the bioinformatics 
tool MOE (Molecular Operating Environment) to generate a 3-D homology model 
of S. pseudintermedius SrtA. A potential structure of SrtA was built and atomic 
coordinates for the protein, including for the active site’s amino acids involved in 
substrate binding, were generated. The predicted 3-D homology model of SrtA with 
a potential inhibitor bound to its active site is shown in Figure 5.4.   
Inhibition of SrtA activity in vitro  
 
To determine the activity of recombinant SrtA, an in vitro functional assay using 
the synthetic SrtA substrate, bacterial sortase substrate III, Abz/DNP (Abz-LPETG-
K(Dnp)-NH2 was performed. Functional SrtA cleaves the substrate between 
threonine (T) and glycine (G) and this is measured by an increase in fluorescence. 
A dose dependent increase in the cleavage of the substrate was observed when 
1μM of recombinant SrtA was used in the FRET assay (Figure 5.5). 
 
Next, to determine the inhibitory potential of the compounds from NCI, recombinant 
SrtA was pre-incubated with the inhibitors at 37°C for 30min and the FRET assay 
was performed. From the first round of screening, four out of the ten compounds 
from NCI (117466, 117922, 64876 and 1847) showed between 40-60% inhibition 
of SrtA. Of these, Compound 1847 consistently showed 50-80% inhibition of 
recombinant SrtA depicted in (Figure 5.6). MTSET which is a known inhibitor of 
SrtA [70] was used as the control and showed 57.5% inhibition in this assay.  
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Figure 5.4  3-D homology model of SrtA.  
3-D homology model of S. pseudintermedius SrtA with a representative inhibitor 
(shown in green) bound to the active site. The β-sheets, α-helices and loop regions 
are indicated in yellow, red and blue respectively. 
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Figure 5.5  SrtA functional assay.  
The activity of recombinant of SrtA was measured using a FRET assay. Varying 
concentrations of the FRET substrate were incubated with 1μM of the enzyme. 
The cleavage of the substrate was monitored by measuring an increase in 
fluorescence.  
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Figure 5.6 First round of screening for inhibitors.  
Compounds from NCI tested for their ability to inhibit SrtA in the in vitro FRET-
based functional assay. Four of the ten compounds showed ~40%-60% inhibition 
of Srt A. The values represent average from three independent experiments. 
(*P<0.05 was considered significant).  
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Since compound 1847 showed promising results, the second search iteration was 
based on the structure of 1847 to identify similar compounds but with higher 
inhibitory potential. Four compounds were identified from the Zinc database. Of 
the four compounds, only one compound, 5930504, showed 51.76% inhibition.  
5510335 and STL223442 showed 9.88% and 13.75% inhibition respectively. 
SKT022091 did not have inhibitory effect on SrtA. However, none of the 
compounds from Zinc were better than the parent compound, 1847 (Figure 5.7). 
 
Inhibition of SrtA Activity during Bacterial Growth 
 
SrtA catalyzes the anchoring of surface proteins with a specific LPXTG motif on to 
the peptidoglycan cell wall during active bacterial growth (log phase). Inhibition of 
SrtA in bacterial cells should result in decreased amounts of cell wall-associated 
proteins harboring the LPXTG motif.  This can be measured indirectly by 
measuring the decrease in the density of cell-wall associated LPXTG proteins. In 
S. pseudintermedius, there are several proteins with a predicted LPXTG motif, 
including but not limited to protein A, clumping factors A and B, fibrinogen binding 
protein and fibronectin binding protein. In this assay, the inhibition of SrtA was 
measured indirectly by measuring the decrease in the amount of Protein A on the 
bacterial surface using flow cytometry. Five representative S. pseudintermedius 
isolates were tested. Isolates 06-3228, 08-1661, NA12 and NA16 showed 38.7%, 
74.3%, 42.8% and 89.4% reduction in the density cell wall-associated Protein A 
compared to the respective controls without the inhibitor for each isolate, as a 
result of SrtA inhibition (Figure 5.8). Isolate NA45 was not affected by compound 
1847. These results suggest that compared to the controls (without inhibitor), the 
bacterial cells exposed to the inhibitor 1847 showed a decrease in the density of 
cell wall-associated Protein A due to inhibition of SrtA.  
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Figure 5.7  Second round of screening for inhibitors.  
Inhibitory effect of compounds from ZINC.  Of the four compounds tested, only 
5930504 showed ~50% inhibition of Srt A in the in-vitro FRET-based functional 
assay. 5510335 and STL223422 showed 10-20% inhibition while STK022091 did 
not have any inhibitory effect on SrtA. The values represent average from three 
independent experiments. (*P<0.05 was considered significant).  
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Figure 5.8  Inhibition of SrtA in whole bacterial cells.  
Four bacterial isolates 08-3228, 08-1661, NA12 and NA16 were grown in presence 
of inhibitor 1847 till exponential log phase. SrtA inhibition was measured indirectly 
by measuring the decrease in the density of cell wall associated Protein A (one of 
the LPXTG proteins targeted by SrtA) using flow cytometry. The values represent 
average from three independent experiments. (*P<0.05 was considered 
significant). Isolate NA45 which does not express functional Protein A on its 
surface was not affected by inhibitor 1847.  
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To determine the effect of inhibitor on bacterial viability, bacterial growth was 
monitored in the presence and absence of inhibitors at varying concentrations. 
Bacterial growth was determined by measuring the turbidity of the culture medium 
at A600. It was found that the bacterial growth remained unaffected in the presence 
of the inhibitor suggesting that the inhibitor affected the function of SrtA but had no 
direct effect on growth of the bacteria. 
 
Discussion 
In the last decade, there has been a steady increase in the incidence of 
microorganisms with resistance to methicillin both in human and veterinary 
medicine [80, 92]. Most of the organisms that display methicillin resistance are also 
multidrug resistant and cannot be treated with conventional antibiotics. This is 
particularly difficult in the veterinary setting due to the limited number of antibiotic 
choices that are approved for treatment [81]. Hence, there is an urgent need for 
the development of novel therapeutics that can be administered either 
prophylactically or after the onset of infection. Ideally, any novel therapeutic should 
not have a high level of selective pressure that is observed with current antibiotics. 
This will help reduce the risk of developing new forms of resistance [177].  
 
Cell wall-associated (CWA) proteins are responsible for virulence and immune 
evasion in staphylococci [126]. SrtA is a cysteine transpeptidase produced by most 
Gram positive bacteria. It catalyzes the anchoring of proteins harboring the LPXTG 
motif on to the peptidoglycan cell wall [58, 62]. Inhibition of SrtA will prevent 
proteins harboring the LPXTG motif from anchoring on to the cell wall, thereby 
preventing the interaction between the CWA proteins and the host. Since this is a 
crucial step in the establishment of infection, inhibiting SrtA would make the 
bacteria less virulent [56, 57, 70, 124]. Inhibition of SrtA has several advantages. 
(a) Firstly, SrtA is expressed on the outside of the bacterial cell membrane which 
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makes it readily accessible to inhibitors without the need for penetrating the cell 
membrane, (b) SrtA inhibition will not affect the viability of the bacteria directly. 
Therefore, the risk of bacteria developing resistance against the inhibitor is greatly 
reduced and (c) there is no known homologue for SrtA in eukaryotes, thus it is 
possible to achieve selectivity more easily. SrtA inhibition has been extensively 
studied in S. aureus [71, 175]. Virtual screening of drug databases to identify 
inhibitors for S. aureus SrtA has also been explored [70, 74].  
 
In this study, recombinant SrtA from S. pseudintermedius was expressed and 
purified from E. coli.  A homology model of the enzyme was generated. Using this 
model, virtual screening of NCI database for compounds that bind to the catalytic 
site of SrtA was performed. Ten compounds were selected and tested for their 
abilities to inhibit recombinant SrtA in an in vitro FRET-based assay. Compound 
1847 consistently showed >50% inhibition in this assay. The structure of 1847 was 
used as the template to screen a second database, Zinc, in an attempt to find 
compounds with higher inhibitory potential. Four compounds were identified and 
tested again using the in vitro FRET-based assay, although none of the new 
compounds were better than the parent compound, 1847. Since 1847 was the 
most promising candidate, it was tested in whole bacterial cells during active 
growth phase to determine its ability to inhibit SrtA. The results showed that in all 
of the bacterial isolates tested, except NA45, there was between 35%-80% 
reduction in the amount of CWA Protein A, suggesting that SrtA inhibition could 
work as an anti-infective therapy against staphylococcal infections. Future 
experiments in this study include analysis of enzyme kinetic parameters, target 
validation using surface plasmon resonance and/or isothermal colorimetry, side 
chain modification to enhance the inhibitory potential of compound 1847 and 
finally, testing the inhibitor in an animal model of S. pseudintermedius infection.  
The role of SrtA in anchoring CWA proteins and its contribution to virulence is not 
just limited to staphylococcal species. SrtA and surface proteins with LPXTG 
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sorting signals have also been studied in streptococcal species and other 
nosocomial pathogens like Enterococcus faecalis, Enterococcus faecium, and 
Clostridium difficile [58]. Therefore, small molecule inhibitors that can specifically 
block sortase-catalyzed transpeptidation reaction could work against a broad 
spectrum of pathogenic, antibiotic-resistant Gram-positive bacteria.  
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CONCLUSION 
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Conclusions and Recommendations 
 
The canine pathogen S. pseudintermedius has been associated with an increased 
prevalence of methicillin resistance and multidrug resistance. Due to the limited 
number of antibiotics available for treatment in the veterinary setting, it is important 
to develop novel strategies to treat or prevent infection. Understanding the nature 
of immune response to S. pseudintermedius infection is crucial for vaccine 
development.  
 
Characterization of the virulence factor Protein A in S. pseudintermedius has 
provided information about the nature of canine IgG binding to this protein. It is 
now evident that the most predominant clonal populations in the United States and 
Europe, ST68 and ST71 respectively, bind higher amounts of canine IgG and anti-
Protein A antibody, suggesting that these sequence types may express a higher 
amount of Protein A on their surface. Protein A binds to canine IgG via its Fc 
region. This binding in the ‘wrong’ orientation facilitates Protein A to function as an 
immune evasion factor by preventing opsonization and phagocytosis. This has 
also been demonstrated in canine blood, neutrophils and DH82 macrophage-like 
cell line wherein pre-incubation of bacteria with anti-Protein A antibody enhances 
phagocytosis. Once the IgG-binding sites on Protein A are identified, it will be 
possible to generate a non-toxigenic form of the protein that can be tested both in 
vitro and in vivo as a potential vaccine candidate.  
 
S. pseudintermedius employs several immune evasion strategies to persist in the 
host and establish infection. Inhibiting one virulence/immune evasion factor may 
not be the best strategy for treatment of infection. Instead, targeting a global 
protein or enzyme that is central to the regulation of multiple virulence factors could 
be a potential strategy to combat infection. Sortase A is a transpeptidase enzyme 
produced by all Gram-positive bacteria that is responsible for anchoring proteins 
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with an LPXTG domain onto the peptidoglycan cell well. Most proteins with an 
LPXTG domain are potent virulence factors. In this study, the possibility of 
inhibiting Sortase A as an anti-infective therapy was explored. 3-D homology 
modeling and molecular dynamic simulation helped map the active site of Sortase 
A. Virtual screening of drug databases provided a list of potential inhibitors that 
were tested both in an in vitro assay and in bacterial cells. Compounds that were 
able to inhibit the activity of Sortase A were identified. Further optimization and 
testing of the compounds in an animal model could prove to be useful in 
determining if co-administration of a Sortase A inhibitor along with antibiotic 
treatment will be a more effective treatment strategy than what is currently being 
followed.  
 
Several studies with S. aureus have indicated that a successful vaccine could be 
one with several different antigenic determinants (multivalent vaccine) that can 
stimulate both B-cell and T-cell responses. Keeping these factors in mind, the 
secretome, surface-associated proteins and IgG-binding proteins from three 
representative sequence types were analyzed by mass spectrometry. From the 
data, eight target proteins were identified across all three sequence types. Further 
testing and characterization of these proteins need to be performed.  
 
This work has laid the foundation for identifying, characterizing and testing proteins 
that could serve as potential vaccine candidates, and explore non-antibiotic 
strategies such as Sortase A inhibition as alternate anti-infective therapy against 
methicillin-resistant S. pseudintermedius infection.    
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